

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [editorial.bmjopen@bmj.com](mailto:editorial.bmjopen@bmj.com)

# BMJ Open

## **Do Koreans use too many moderate-intensity statins? Evidence from 13-years of statin utilization for new users in South Korea**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026603
Article Type:	Research
Date Submitted by the Author:	11-Sep-2018
Complete List of Authors:	Son, Kyung-Bok; Ewha Womans University, Bae, SeungJin; Ewha Womans University, College of Pharmacy
Keywords:	statins, statin utilization, a retrospective study, South Korea

SCHOLARONE™  
Manuscripts  
view only

# Do Koreans use too many moderate-intensity statins?

## Evidence from 13-years of statin utilization for new users

### in South Korea

<sup>a)</sup> Kyung-Bok Son (Corresponding author), <sup>b)</sup> Seungjin Bae

a) College of Pharmacy, Ewha Womans University, Seoul, South Korea

Tel) +82-2-3277-5927, [sonkyungbok@gmail.com](mailto:sonkyungbok@gmail.com)

b) College of Pharmacy, Ewha Womans University, Seoul, South Korea

[Tel\) +82-2-3277-5927, sonkyungbok@gmail.com](mailto:sonkyungbok@gmail.com)

Kyung-Bok Son

College of Pharmacy, Ewha Womans University, Seoul, South Korea

52 Ewhayeodae-gil, Seodaemun-gu, Seoul, 03760, Korea

Tel) +82-2-3277-5927, Fax) +82-2-3277-4599

[sonkyungbok@gmail.com](mailto:sonkyungbok@gmail.com)

## Do Koreans use too many moderate-intensity statins? Evidence from 13-years of statin utilization for new users in South Korea

Objective: Given market size of statins and a number of “me-too” drugs and generics, statin utilization has been the subject of great interest in the perspective of public health. This study analyzed utilization of statins for new statin users and assessed market dynamics of statins in Korea from 2003 to 2015.

Design: This study is a retrospective observational study focusing on the utilization of statins for new users.

Setting: The yearly claims data for statins between 2002 and 2015 were retrieved from the National Health Insurance Service-National Sample Cohort.

Main outcome measure: This study examine characteristics of new statin users and prescribed statin drugs over the last thirteen years, investigate the association between medical history of patients and intensity of statins, and analyze market dynamics of statins using interrupted time series analysis.

Results: This 13-year longitudinal study of a sample cohort provided by the NHIS found that the number of new statin users has increased from 8,205 in 2003 to 15,514 in 2015. Most new users were initiated on a monotherapy that was prescribed at primary healthcare institutions. Use of

1  
2  
3  
4 moderate-intensity statins increased, notably at primary healthcare institutions from 48% in 2003  
5  
6  
7 to 95% in 2015. We could not observe substantial differences in prescription of statins in groups  
8  
9  
10 with selected diseases history through the study period. Lastly, we found market invasion or  
11  
12 switch of statins among new statin users in the market, specifically at primary healthcare  
13  
14  
15 institutions. In addition, we noted that the marketing of generics immediately expand markets  
16  
17  
18 particularly in primary healthcare institutions in the interrupted time series model.

19  
20 Conclusion: Fierce market competition among statins is closely related with expansion of market  
21  
22  
23 of new statin users, particularly in primary healthcare institutions. Furthermore, the pricing and  
24  
25  
26 marketing strategies of manufacturers might encourage physicians to prescribe moderate-  
27  
28  
29 intensity statins in Korea.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

## Strengths and limitations of this study

This study notably analyzed utilization of statins for new statin users and assessed market dynamics of statins in Korea from 2003 to 2015.

The yearly claims data for statins between 2002 and 2015 were retrieved from the National Health Insurance Service-National Sample Cohort that is composed of approximately 1 million individuals (around 2% of the population).

The market of statins in Korea was dynamic. We noted that the marketing of generics immediately expand markets particularly in primary healthcare institutions in the interrupted time series model.

It seems that fierce market competition among statins, including price competition, is closely related with the expansion of markets of new statin users, particularly in primary healthcare institutions. Further investigation is needed to assess market dynamics in Korea.

1  
2  
3  
4 A funding statement:  
5  
6  
7

8 This research received no specific grant from any funding agency in the public, commercial or  
9  
10  
11 not-for-profit sectors.  
12  
13  
14  
15  
16  
17

18 A competing interests statement  
19  
20  
21

22 Non-financial and any similar financial associations that may be relevant to the submitted  
23  
24  
25 manuscript.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

## Introduction

Cardiovascular diseases (CVDs) account for 31% of all global deaths, taking the lives of 17.7 million people annually <sup>1</sup>. Similarly, CVDs are among the leading causes of death in South Korea (hereafter Korea) <sup>2,3</sup>. Hypercholesterolemia is a well-established, but modifiable risk factor for CVDs <sup>4-8</sup>. Lifestyle changes and several types of medications have been recommended to control blood lipid levels. Among the medications, statins are a major drug class that functions in reducing low-density lipoprotein cholesterol (LDL-C) <sup>9-12</sup>. Specifically, statins are recommended by several clinical guidelines, including the American College of Cardiology/American Heart Association (ACC/AHA) Guideline and the European Society of Cardiology (ESC) and the UK's National Institute for Health and Care Excellence Guideline, as the drug of choice for reduction of blood lipids to prevent CVDs.

In recent decades, statins have been the most commonly prescribed drugs in the world, and their global market sales reached approximately 28.5 billion dollars in 2014 <sup>13</sup>. Studies from the United States reported substantial increases in prescription rates of statins, including increased prescribed daily doses of statins <sup>14</sup>. Furthermore, ACC/AHA Guidelines recommend that patients with a CVD history or with CVD risk factors, such as high LDL-C and diabetes, receive moderate- to high-intensity statins <sup>10</sup>. Based on the guidelines, use of statins for patients with a disease history or



1  
2  
3  
4 risk factors would be increased. Likewise, drug expenditure for statins has increased from 496  
5  
6 billion won in 2010 to 786 billion won in 2016 in Korea <sup>2,3</sup>. It should be noted that there are many  
7  
8 “me-too” drugs, including generics or follow on drugs, under the statin category <sup>12</sup>. For example,  
9  
10 atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin, as well as  
11  
12 a number of generics, are now available for hypercholesterolemia patients in the Korean market.  
13  
14  
15  
16  
17  
18  
19  
20

21 Given the market size of statins and a number of “me-too” drugs and generic statins, statin  
22  
23 utilization, including switching drugs, in health systems has been the subject of considerable  
24  
25 interest in the perspective of clinical pharmacy and public health <sup>15-21</sup>. However, notably few  
26  
27 studies have dealt empirically with the issue or include real-world data with statin users, especially  
28  
29 in Korea. Meanwhile, it was reported that drug switching among statin users is low in Korea <sup>2</sup>.  
30  
31 Therefore, we selected new statin users to understand statin utilization and market dynamics of  
32  
33 statins in Korea. Given the limited drug switching among statin users, analysing statin utilization of  
34  
35 new users could be used as an important resource to evaluate the use of statins and to assess  
36  
37 market dynamics of statins in Korea.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 This study analysed the utilization of statins for new statin users and assessed the market  
51  
52 dynamics of statins. Specifically, this study examined characteristics of new statin users and the  
53  
54

1  
2  
3  
4 prescribing of statin drugs over the last thirteen years, investigated the association between  
5  
6 medical history of patients and intensity of statins, and analysed market dynamics of statins,  
7  
8  
9 including market penetration and switching among new statin users.  
10  
11  
12  
13  
14  
15

## 16 Methods

17  
18  
19  
20  
21 This study used a real-world sample cohort dataset, for the period of 2002 to 2015. Therefore, we  
22  
23 could examine trends in the prescription of statins over the long term in Korea. We also added  
24  
25 information on the characteristics of new statin users, statin drugs, and healthcare institutions to  
26  
27 understand statin utilization. Furthermore, we added information on statin drugs, specifically the  
28  
29 entry of generics and price fluctuations of new medicines, to analyse market penetration and  
30  
31 market switching among new statin users.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

### 40 Data source

44 This study used a population-based cohort dataset provided by the National Health Insurance  
45  
46 Service-National Sample Cohort (NHIS-NSC)<sup>22</sup>. The dataset is comprised of approximately 1  
47  
48 million individuals (approximately 2% of the population) selected randomly from South Koreans,  
49  
50 which total 45 million people, with national claims data for the period from January 1, 2002, to  
51  
52  
53  
54

1  
2  
3  
4 December 31, 2015. The cohort dataset consists of four databases on participants' insurance  
5  
6 eligibility, medical treatments, medical care institutions, and general health examinations <sup>22</sup>.  
7  
8 Specifically, the dataset provides information on demographic characteristics, disease diagnosis,  
9  
10 treatments and related medical expenditure, and prescription data.  
11  
12  
13  
14  
15  
16

### 17 Study design

18  
19  
20  
21 This study is interested in new statin users. New statin users were defined as those who had not  
22  
23 been prescribed any statin in the year prior to the date of the first statin prescription observed in  
24  
25 the cohort dataset <sup>23</sup>. Therefore, new statin users in each year from 2003 to 2015 were included in  
26  
27 the study population of each year. Specifically, the first prescription for outpatients that included  
28  
29 any statin was set as an index date and analysed in the study.  
30  
31  
32  
33  
34  
35  
36  
37

38 The studied drugs include the statins atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin,  
39  
40 rosuvastatin, and simvastatin. The doses of the individual drugs marketed in Korea are as follows:  
41  
42 atorvastatin 10 mg, 20 mg, 40 mg, and 80 mg; pravastatin 5 mg, 10 mg, 20 mg, and 40 mg;  
43  
44 rosuvastatin 5 mg, 10 mg, and 20 mg; and simvastatin 10 mg, 20 mg, 40 mg, and 80 mg (drug  
45  
46 code, Appendix 1). In this study, we defined mono-therapy as only one statin prescription, while  
47  
48 we defined combination therapy as prescription for a statin plus other lipid-lowering drugs,  
49  
50  
51  
52  
53  
54

1  
2  
3  
4 including fibrates or ezetimibe.  
5  
6  
7  
8  
9

10  
11 Statins were grouped into three levels of intensity <sup>10,24</sup>: high-intensity statins; moderate-intensity  
12  
13 statins; and low-intensity statins. High-intensity statins include atorvastatin  $\geq 40$  mg/day,  
14  
15 rosuvastatin  $\geq 20$  mg/day and simvastatin  $\geq 80$  mg/day. Low-intensity statins include atorvastatin  
16  
17  $< 10$  mg/day, rosuvastatin  $< 5$  mg/day, simvastatin  $< 20$  mg/day, pravastatin  $< 40$  mg/day, lovastatin  
18  
19  $< 40$  mg/day and fluvastatin  $< 80$  mg/day. Lastly, moderate-intensity statins include 10 mg/day  $\leq$   
20  
21 atorvastatin  $< 40$  mg/day, 5 mg/day  $\leq$  rosuvastatin  $< 20$  mg/day, 20 mg/day  $\leq$  simvastatin  $< 80$   
22  
23 mg/ day, pravastatin  $\geq 40$  mg/day, lovastatin  $\geq 40$  mg/ day and fluvastatin  $\geq 80$  mg/day. Daily  
24  
25 doses can be calculated from the prescription data.  
26  
27  
28  
29  
30  
31  
32  
33  
34

35 All new statin users were classified based on their disease history, including hypertension (I10-I15),  
36  
37 diabetes (E10-E14), diseases of arteries, arterioles and capillaries (I70-I79), ischaemic heart disease  
38  
39 (I20-I25), cerebrovascular diseases (I60-I69), chronic obstructive pulmonary disease (J44), heart  
40  
41 failure (I50), chronic kidney diseases (N17-N19), and atrial fibrillation (I48). Disease history was  
42  
43 identified by the International Classification of Disease, 10<sup>th</sup> edition (ICD-10). Among these  
44  
45 diseases, diabetes, diseases of arteries, arterioles and capillaries, cerebrovascular diseases, and  
46  
47 heart failure are related to the use of statins for CVD prevention <sup>25-27</sup>. Individuals were identified  
48  
49  
50  
51  
52  
53  
54

1  
2  
3  
4 as having a disease history of the specific disease if they had a primary diagnosis that  
5  
6 corresponded to each diagnosis within three years prior to the first prescription date <sup>27,28</sup>. In  
7  
8  
9 addition, we searched the market of statins in Korea, including price information and the entry of  
10  
11  
12 new drugs and follow on drugs, on the website of the Ministry of Food and Drug Safety (MFDS)  
13  
14  
15 and the Health Insurance Review and Assessment Service (HIRA).

#### 21 Data analysis

22  
23 This study used descriptive statistics to examine characteristics of new statin users and prescribed  
24  
25 statin drugs, employed the  $\chi^2$  test to investigate the associations between certain disease history  
26  
27 and prescription of moderate- or high-intensity statins, and applied interrupted time series  
28  
29 analysis to understand the market dynamics of statins. In time series analysis, we added the year  
30  
31 of marketing of generics to estimate the effect of marketing generics on the market, specifically  
32  
33 newly prescribed statin users <sup>29</sup>. We presented the result of simple linear regression before and  
34  
35 after the marketing of generics. Data management and analysis were performed using the R  
36  
37  
38 statistical software (version 3.4.1). P-values under 0.05 were considered to be significance.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

#### 49 Ethical statement

50  
51 This study used a de-identified secondary dataset. Therefore, it was exempted from review by the  
52  
53  
54

1  
2  
3  
4 Institutional Review Board (IRB) of Ewha Womans University (IRB No. 158-10).  
5  
6  
7  
8

## 9 10 Results

11  
12  
13  
14 Table 1 presents characteristics of new statin users over time. The number of new statin users  
15  
16 increases from 8,205 in 2003 to 15,514 in 2015. There have been more female new users than  
17  
18 male new users, while the portion of female new statin users steadily declined from 56.5% in 2003  
19  
20 to 50.4% in 2015. During this period, the average age of new statin users remained steady (54.31  
21  
22 – 56.52 years old). We also sorted new statin users by their income quintile. The portion of the  
23  
24 first quintile (the lowest income) increased from 13% in 2003 to 16% in 2015, while the portion of  
25  
26 the fifth quintile (the highest income) decreased from 33% in 2003 to 30% in 2015. In 2003,  
27  
28 hypertension accounted for the highest portion of comorbidities (55%), followed by diabetes  
29  
30 (37%), ischaemic heart disease (21%), diseases of arteries, arterioles and capillaries (14%), and  
31  
32 cerebrovascular diseases (12%). These trends remained steady in 2015. However, it is noteworthy  
33  
34 that the proportion of disease of arteries, arterioles and capillaries increased, while that of  
35  
36 hypertension and ischaemic heart disease decreased.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 Table 2 shows characteristics of prescribed statin drugs among new statin users. The majority of  
51  
52 patients were prescribed with a single statin (monotherapy) when they started  
53  
54

1  
2  
3  
4 hypercholesterolemia treatment, while few new statin users were prescribed combination therapy  
5  
6  
7 during the study period.  
8  
9  
10

11  
12  
13 The market for monotherapy statins is dynamic. In 2003, simvastatin (37%) was the most  
14  
15 prescribed statin, followed by lovastatin (30%) and atorvastatin (18%). The market share of  
16  
17 simvastatin had been the highest in the market from 2003 (37%) to 2007 (50%). During this  
18  
19 period, the market share of atorvastatin was steady (18-20%), while the market share of lovastatin  
20  
21 decreased from 30% in 2003 to 4% in 2007. Similarly, the market share of simvastatin decreased  
22  
23 after 2008, while the market share of atorvastatin increased and maintained the highest from 46%  
24  
25 in 2008 to 66% in 2013. Lastly, the market share of rosuvastatin increased from 8% in 2013 to 36%  
26  
27 in 2015, while that of atorvastatin decreased from 66% to 49% during the same period. In 2015,  
28  
29 statins for new users were an oligopoly market: atorvastatin (49%) was the most prescribed statin,  
30  
31 followed by rosuvastatin (36%).  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 In 2003, the prescription rates of low-intensity and moderate-intensity statins were 43% and 57%,  
45  
46 respectively. However, the prescription rate of moderate-intensity statins consistently increased to  
47  
48 92% in 2015, while the prescription rate of low-intensity statins decreased to 3% in 2015. In  
49  
50 addition, the use of high-intensity statins steadily increased during the study period. We also  
51  
52  
53  
54

1  
2  
3  
4 examined health care institutions that prescribed statins. In 2003, 63% of new statin users were  
5  
6 prescribed at primary healthcare institutions followed by secondary- (20%) and tertiary care  
7  
8 institutions (14%). During the study period, the portion of new users prescribed at primary and  
9  
10 tertiary healthcare institutions decreased, while the portion of new users prescribed at secondary  
11  
12 healthcare institutions increased. In 2015, 58% of new statin users were prescribed at primary  
13  
14 healthcare institutions followed by secondary- (29%) and tertiary healthcare institutions (11%).  
15  
16  
17  
18  
19  
20  
21  
22  
23

24 Figure 1 shows statin prescription by health care institutions and the intensity of prescribed statins.  
25  
26 The first graph in Figure 1 presents overall patterns of the prescription rates of low-, moderate-,  
27  
28 and high-intensity statins in all institution types. The remaining graphs indicate patterns of  
29  
30 prescription rates in primary-, secondary-, and tertiary healthcare institutions. We found that  
31  
32 prescription rates of moderate-intensity statins were high in primary healthcare institutions, while  
33  
34 those of high-intensity statins were high in tertiary care institutions. It is interesting to note that  
35  
36 prescription rates of moderate-intensity statins in primary-, secondary-, and tertiary healthcare  
37  
38 institutions in 2003 was 48%, 69%, and 78%, respectively. However, prescription rates of  
39  
40 moderate-intensity statins changed in primary, secondary, and tertiary healthcare institutions in  
41  
42 2015: 95%, 90%, and 84%, respectively.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54



1  
2  
3  
4 Figure 2 presents prescription rates of selected statins, including atorvastatin, rosuvastatin, and  
5  
6 simvastatin, during the study period. The first graph in Figure 2 shows market shares of selected  
7  
8 statins among new statin users. We noted two points in the perspective of market dynamics. The  
9  
10 first market dynamic occurred during 2007-2009 and consisted of the market invasion of  
11  
12 atorvastatin. Specifically, atorvastatin penetrated the market of simvastatin in this period. Similarly,  
13  
14 the second market dynamic occurred during 2013-2015 and consisted of the market invasion of  
15  
16 rosuvastatin. Rosuvastatin penetrated market of atorvastatin in this period. The remaining graphs  
17  
18 present new statin users of selected statins by primary, secondary, and tertiary healthcare  
19  
20 institutions. In this figure, we conclude that the majority of market switching of statins among new  
21  
22 statin users occurred immediately at primary healthcare institutions.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

35 Table 3 indicates the associations between certain disease histories and the prescription of  
36  
37 moderate- or high-intensity statins. Interestingly, no substantial differences in the prescription of  
38  
39 statins were observed through the study period in groups with histories of diseases of arteries,  
40  
41 arterioles and capillaries. Furthermore, patients with diabetes and cerebrovascular diseases were  
42  
43 less likely to be prescribed moderate- or high-intensity statins in several selected years. For  
44  
45 instance, odds ratios were calculated at 0.78 and ranged from 0.67 to 0.91 with 95% confidence  
46  
47 interval in 2012 for patients with diabetes.  
48  
49  
50  
51  
52  
53  
54

## Discussions

This 13-year longitudinal study of a sample cohort provided by the NHIS found that the number of new statin users has increased over time from 8,205 in 2003 to 15,514 in 2015. Most new users were initiated on a monotherapy that was prescribed at primary healthcare institutions. In addition, the use of moderate-intensity statins increased, notably at primary healthcare institutions, during the study period. Specifically, the prescription rate of moderate-intensity statins at primary healthcare institutions was low (48%) in 2003. However, the figure was doubled in 2015 (95%). Lastly, the market of statins was dynamic. For instance, we found market invasion or switching of statins among new statin users in the market, specifically at primary healthcare institutions.

The characteristics of new statin users and health care institutions that prescribed statins were similar to other studies that investigated prescription patterns of all statin users in Korea<sup>23</sup>. In addition, this finding is consistent with other countries<sup>23,30-33</sup>. It is noteworthy to compare the results of statin prescription for new users with those of Taiwan<sup>23</sup>. First, the intensity of prescribed statin therapy was higher in Korea. For instance, the portion of moderate-intensity statins among new statin users in Taiwan has remained at 70% since 2007. However, the portion of moderate-

1  
2  
3  
4 intensity statins in Korea was above 90% since 2007. In addition, the market in Korea was more  
5  
6  
7 dynamic than that of Taiwan during the study period. Furthermore, we found no substantial  
8  
9  
10 differences in the prescription of moderate- or high-intensity statins in groups with histories of  
11  
12 hypertension, diabetes, diseases of arteries, arterioles and capillaries, cerebrovascular diseases, and  
13  
14  
15 ischaemic heart disease in Korea.

16  
17  
18  
19  
20  
21 Second, the most commonly used statin changed during the study period in Korea, while  
22  
23  
24 atorvastatin has been the most prescribed statin during 2002-2011 in Taiwan <sup>23</sup>. For instance,  
25  
26  
27 simvastatin had the highest prescription rate until 2007, while atorvastatin had the highest  
28  
29  
30 prescription rate after 2008. It should be noted that generics of atorvastatin were available with  
31  
32  
33 discounted prices compared to the originals of the previous year (approximately 68%) in 2008,  
34  
35  
36 and the price of the originals was discounted approximately 20% compared to the previous year.  
37  
38 We could find similar results in the case of rosuvastatin. Generics of rosuvastatin were available in  
39  
40  
41 2010 and the prices of generics were 451 won, 676 won, and 890 won for 5 mg, and 10 mg, and  
42  
43  
44 20 mg, respectively, which account for approximately 68% of the original counterparts. In such a  
45  
46  
47 case of the introduction of generics, the prices of originals would be decreased to 80% compared  
48  
49  
50 to the previous year. However, price reduction was deferred until 2014 in this case. In the end, the  
51  
52  
53 price of original rosuvastatin decreased to approximately 80% compared to that of the previous  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 year. It is interesting to note the prescription rates of rosuvastatin: the market share of  
5  
6  
7 rosuvastatin in 2009 was 7% and slightly increased 9% in 2010 when generics with discounted  
8  
9 prices (approximately 32%) were marketed, and later increased 33% in 2014 when prices of  
10  
11  
12 generics were discounted (approximately 20%).  
13

14  
15  
16  
17  
18 These comparisons reveal that there is room for investigating the rational use of statins in Korea.  
19  
20  
21 Given these cases of atorvastatin and rosuvastatin, we might conclude that fierce market  
22  
23  
24 competition among statins, including price competition, is closely related to the expansion of  
25  
26  
27 markets by the addition of new statin users. Table 4 presents results of segmented regression  
28  
29  
30 analysis using the interrupted time series method:  $\beta_0$  is the pre period intercept;  $\beta_1$  is the pre  
31  
32  
33 period slope (baseline time trend);  $\beta_2$  is the immediate effect of the event on the intercept; and  $\beta_3$   
34  
35  
36 is the slope change after the event. In the case of atorvastatin, the immediate effect of marketing  
37  
38  
39 generics was 3,236 new users ( $p < 0.001$ ), and the growth rate was increased by 2,687 new users  
40  
41  
42 per year ( $p < 0.005$ ) compared with previous trends. Similar trends were found in the case of  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
rosuvastatin.

It is interesting to analyse market expansion by health care institutions. In both cases, the  
immediate effect of the event was large in primary healthcare institutions. For instance, the

1  
2  
3  
4 immediate effect of marketing generics of rosuvastatin was 3,163 users ( $p < 0.0000$ ) and 517 users  
5  
6  
7 ( $p < 0.005$ ) in primary- and secondary- healthcare institutions, respectively. However, the  
8  
9 immediate effect of generics in tertiary care institutions was marginal and insignificant: 16.2 ( $p$   
10  
11  $= 0.78$ ) for atorvastatin and 7.1 (0.95) for rosuvastatin. These results demonstrate that the  
12  
13 marketing of generics immediately expands markets, particularly in primary healthcare institutions.  
14  
15 In addition, the growth rates, sorted by health care institutions, after the introduction of generics  
16  
17 vary according to drugs. For instance, the growth rate of atorvastatin was in the order of primary-,  
18  
19 secondary-, and tertiary healthcare institutions, 1,597 ( $p < 0.0001$ ), 736 ( $p < 0.05$ ), and 352 ( $p$   
20  
21  $< 0.001$ ), respectively, while that of simvastatin was in the order of secondary-, primary-, and  
22  
23 tertiary healthcare institutions, 2,243 ( $p < 0.0001$ ), 178 ( $p < 0.05$ ), and 33 ( $p = 0.80$ ), respectively,  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

35 In addition, we found the pricing and marketing strategies of manufacturers might encourage  
36  
37 physicians to prescribe moderate-intensity statins. For instance, the manufacturer discounted the  
38  
39 price of simvastatin 40 mg (approximately 34%), and the price was the same as simvastatin 20 mg.  
40  
41 Likewise, the other manufacturer that produce atorvastatin utilized the same strategy. Specifically,  
42  
43 the manufacturer discounted the price of atorvastatin 40 mg (35%), and the price was the same  
44  
45 as atorvastatin 20 mg in 2003. In addition, the manufacturer discounted the price of atorvastatin  
46  
47 20 mg (30%), which was the same price as atorvastatin atorvastatin 10 mg. In addition, the  
48  
49  
50  
51  
52  
53  
54

1  
2  
3  
4 manufacturer marketed atorvastatin 80 mg in the market to preempt the high-strength statins  
5  
6  
7 market.  
8  
9  
10

11  
12  
13 This study notably analysed the utilization of statins for new statin users and assessed the market  
14  
15 dynamics of statins over the last thirteen years with a real-world dataset provided by the NHIS.  
16  
17 However, this study has several limitations. First, this study used claims data that does not contain  
18  
19 information on biochemical test data of patients, such as LDL cholesterol level. This finding means  
20  
21 that we could not assess prescription patterns by disease severity. In addition, the claims data  
22  
23 does not contain information on whether the prescribed drugs were originals or generics.  
24  
25 Therefore, further research is needed to assess the impact of generics on the market, including  
26  
27 the contribution to market expansion by originals and generics, respectively. Second, this study  
28  
29 only used the first prescription that included any statins. Therefore, switches among statins were  
30  
31 not included in the study. However, it would be reasonable to assume that switches among statins  
32  
33 would be low in the Korean market <sup>2</sup>.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

## 47 Conclusions

48  
49  
50

51 This 13-year longitudinal study of a sample cohort provided by the NHIS found that the number  
52  
53  
54

1  
2  
3  
4 of new statin users has increased over time from 8,205 in 2003 to 15,514 in 2015, and the market  
5  
6  
7 of statins for new statin users has been dynamic for the same period. Furthermore, it is  
8  
9  
10 noteworthy that the portion of new statin users that were prescribed moderate- or high-intensity  
11  
12 statins has increased from 57% in 2003 to 95% in 2015. In addition, no substantial differences in  
13  
14 the prescriptions of statins were observed through the study period in groups with selected  
15  
16 disease histories. These interesting findings reveal that there is room to investigating the rational  
17  
18 use of statins in Korea. It seems that fierce market competition among statins, including price  
19  
20 competition, is closely related with the expansion of markets of new statin users, particularly in  
21  
22 primary healthcare institutions. Furthermore, the pricing and marketing strategies of  
23  
24 manufacturers might encourage physicians to prescribe moderate-intensity statins for new statin  
25  
26 users.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

#### 41 **Author's contribution**

42  
43  
44  
45  
46 KS designed the study, collected and analyzed data, and wrote the manuscript.  
47  
48

49 SB revised the paper for important intellectual content.  
50  
51

52 All authors read and approved the final manuscript.  
53  
54

## References

1. WHO. Cardiovascular diseases (CVDs). 2016; [http://www.who.int/cardiovascular\\_diseases/en/](http://www.who.int/cardiovascular_diseases/en/). Accessed 10 Aug, 2018.
2. Hye-Jae L, Tae-Jin L. Impact of Price Control on Drug Expenditure and Factors Associated with the Drug Switch among Statins: Analysis of HIRA-NPS Data. *Health Policy and Management (HPM)*. 2013;23(2):112-123.
3. Shin S, Song H, Jang S, Sung Y. Development of the outcome index of hyperlipidemia treatments (lipid lowering agents). *Seoul: Health Insurance Review and Assessment Service*. 2009.
4. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. *Journal of the American College of Cardiology*. 2004;44(3):720-732.
5. Sharrett AR, Ballantyne C, Coady S, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein (a), apolipoproteins AI and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. *Circulation*. 2001;104(10):1108-1113.
6. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. *Circulation*. 1998;97(18):1837-1847.
7. Lee KH, Jeong MH, Ahn Y, Cho MC, Kim CJ, Kim YJ. New horizons of acute myocardial infarction: from the Korea Acute Myocardial Infarction Registry. *Journal of Korean medical science*. 2013;28(2):173-180.
8. Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. *The Lancet*. 1999;353(9147):89-92.
9. Prevention EAfC, Rehabilitation, Reiner Z, et al. ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *Eur Heart J*. 2011;32(14):1769-1818.
10. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology*. 2014;63(25 Part B):2889-2934.
11. NICE Clinical Guideline 181. *Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease 2014*. London: National Clinical Guideline Centre;2014.
12. Weng TC, Yang YHK, Lin SJ, Tai SH. A systematic review and meta-analysis on the



- 1  
2  
3  
4 therapeutic equivalence of statins. *Journal of clinical pharmacy and therapeutics*.  
5 2010;35(2):139-151.  
6  
7 13. IMS Institute for Healthcare Informatics. *Top 20 global therapy areas 2014*. England and  
8 Wales: IMS Health MIDAS;2014.  
9  
10 14. IMS Institute for Healthcare Informatics. *The global use of medicines: outlook through*  
11 *2016*. IMS Institute for Healthcare Informatics;2012.  
12  
13 15. Stargardt T. The impact of reference pricing on switching behaviour and healthcare  
14 utilisation: the case of statins in Germany. *The European Journal of Health Economics*.  
15 2010;11(3):267-277.  
16  
17 16. Ahn E, Shin DW, Yang H-k, et al. Treatment gap in the national health-screening program  
18 in Korea: claim-based follow-up of statin use for sustained Hypercholesterolemia. *Journal*  
19 *of Korean medical science*. 2015;30(9):1266-1272.  
20  
21 17. Kwon H-Y, Godman B. Do newly marketed generic medicines expand markets using  
22 descriptive time series analysis and mixed logit models? Korea as an exemplar and its  
23 implications. *BMC health services research*. 2016;16(1):130.  
24  
25 18. Sakshaug S, Furu K, Karlstad Ø, Rønning M, Skurtveit S. Switching statins in Norway after  
26 new reimbursement policy—a nationwide prescription study. *British journal of clinical*  
27 *pharmacology*. 2007;64(4):476-481.  
28  
29 19. Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of  
30 switching patients from atorvastatin to simvastatin and losartan to candesartan in a  
31 primary care setting: 2 years on. *International journal of clinical practice*. 2008;62(3):480-  
32 484.  
33  
34 20. Health Insurance Review and Assessment Service. *The results of clinical effectiveness and*  
35 *cost-effectiveness of hyperlipidemia treatments*. Seoul: Health Insurance Review and  
36 Assessment Service;2009.  
37  
38 21. Germany Federal Joint Committee. *Explanatory statements on the grouping of statins*.  
39 Federal Joint Committee;2004.  
40  
41 22. Lee J, Lee JS, Park S-H, Shin SA, Kim K. Cohort profile: the national health insurance  
42 service—national sample cohort (NHIS-NSC), South Korea. *International journal of*  
43 *epidemiology*. 2016;46(2):e15-e15.  
44  
45 23. Hsieh HC, Hsu JC, Lu CY. 10-year trends in statin utilization in Taiwan: a retrospective study  
46 using Taiwan's National Health Insurance Research Database. *BMJ open*. 2017;7(5):e014150.  
47  
48 24. Rosenson RS, Kent ST, Brown TM, et al. Underutilization of high-intensity statin therapy  
49 after hospitalization for coronary heart disease. *Journal of the American College of*  
50 *Cardiology*. 2015;65(3):270-277.  
51  
52 25. Finegold JA, Manisty CH, Goldacre B, Barron AJ, Francis DP. What proportion of  
53 symptomatic side effects in patients taking statins are genuinely caused by the drug?  
54

- 1  
2  
3  
4 Systematic review of randomized placebo-controlled trials to aid individual patient choice.  
5 *European journal of preventive cardiology*. 2014;21(4):464-474.  
6  
7 26. Alberton M, Wu P, Druyts E, Briel M, Mills E. Adverse events associated with individual  
8 statin treatments for cardiovascular disease: an indirect comparison meta-analysis. *QJM:*  
9 *An International Journal of Medicine*. 2011;105(2):145-157.  
10  
11 27. Lo Re III V, Haynes K, Goldberg D, et al. Validity of diagnostic codes to identify cases of  
12 severe acute liver injury in the US Food and Drug Administration's Mini-Sentinel  
13 Distributed Database. *Pharmacoepidemiology and drug safety*. 2013;22(8):861-872.  
14  
15 28. Chen GL, Hsiao FY, Dong YH, Shen LJ, Wu FLL. Statins and the risk of liver injury: a  
16 population-based case-control study. *Pharmacoepidemiology and drug safety*.  
17 2014;23(7):719-725.  
18  
19 29. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of  
20 interrupted time series studies in medication use research. *Journal of clinical pharmacy*  
21 *and therapeutics*. 2002;27(4):299-309.  
22  
23 30. Walley T, Folino-Gallo P, Stephens P, Van Ganse E, Group E. Trends in prescribing and  
24 utilization of statins and other lipid lowering drugs across Europe 1997–2003. *British*  
25 *journal of clinical pharmacology*. 2005;60(5):543-551.  
26  
27 31. Ferrajolo C, Arcoraci V, Sullo MG, et al. Pattern of statin use in southern Italian primary  
28 care: can prescription databases be used for monitoring long-term adherence to the  
29 treatment? *PloS one*. 2014;9(7):e102146.  
30  
31 32. Svensson E, Nielsen RB, Hasvold P, Aarskog P, Thomsen RW. Statin prescription patterns,  
32 adherence, and attainment of cholesterol treatment goals in routine clinical care: a Danish  
33 population-based study. *Clinical epidemiology*. 2015;7:213.  
34  
35 33. O'Keeffe AG, Nazareth I, Petersen I. Time trends in the prescription of statins for the  
36 primary prevention of cardiovascular disease in the United Kingdom: a cohort study using  
37 The Health Improvement Network primary care data. *Clinical epidemiology*. 2016;8:123.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

For peer review only

**Table 1. Characteristics of new statin users over time**

	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015
<b>Number of new statin users</b>	8,205	8,835	11,181	12,564	12,774	13,333	15,139	14,713	14,374	14,639	14,117	15,731	15,514
<b>Sex</b>													
Female	56.5%	55.0%	56.8%	55.8%	54.8%	54.3%	55.2%	54.6%	53.2%	53.1%	52.0%	50.7%	50.4%
<b>Age</b>													
Mean	54.40	54.31	55.15	55.61	55.62	55.48	55.61	55.71	55.58	55.65	55.57	56.52	55.90
SD	11.82	12.00	12.15	12.47	12.68	12.52	12.51	12.39	12.46	12.71	12.89	12.79	12.75
<b>Income level (the quintile)</b>													
The first	13%	14%	15%	15%	15%	14%	15%	15%	15%	15%	16%	16%	16%
The second	13%	13%	12%	14%	13%	14%	14%	15%	15%	15%	14%	15%	15%
The third	17%	17%	18%	16%	18%	18%	18%	17%	18%	17%	17%	17%	17%
The fourth	24%	23%	22%	23%	23%	23%	23%	23%	22%	22%	23%	22%	22%
The fifth	33%	32%	33%	32%	32%	31%	30%	31%	30%	30%	30%	30%	30%
<b>Comorbidities</b>													
Hypertension	N/A	55%	59%	58%	58%	56%	54%	53%	53%	52%	52%	48%	
Diabetes		37%	39%	40%	39%	37%	36%	36%	37%	38%	41%	39%	
DoA		14%	17%	20%	24%	25%	25%	23%	22%	21%	22%	20%	
IHD		21%	22%	22%	21%	19%	19%	19%	18%	17%	18%	16%	
CeVD		12%	13%	15%	15%	15%	15%	14%	15%	15%	14%	14%	
COPD		5%	6%	6%	6%	5%	5%	5%	5%	5%	5%	4%	
Heart failure		5%	4%	4%	4%	3%	4%	4%	4%	4%	4%	4%	
CKD		2%	2%	2%	2%	2%	2%	2%	2%	3%	3%	3%	
Afib		2%	2%	2%	3%	2%	2%	2%	2%	2%	3%	2%	

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

Notes: DoA: diseases of arteries, arterioles and capillaries; IHD: ischemic heart disease; CeVD: cerebrovascular diseases; COPD: chronic obstructive pulmonary disease; CKD: chronic kidney diseases; and Afib: atrial fibrillation

For peer review only

**Table 2. Characteristics of prescribed statin drugs among new statin users**

	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015
Number of new statin users	8,205	8,835	11,181	12,564	12,774	13,333	15,139	14,713	14,374	14,639	14,117	15,731	15,514
<b>Monotherapy</b>	<b>100%</b>	<b>100%</b>	<b>99%</b>	<b>98%</b>	<b>97%</b>	<b>98%</b>	<b>97%</b>	<b>97%</b>	<b>95%</b>	<b>94%</b>	<b>95%</b>	<b>96%</b>	<b>95%</b>
Atorvastatin	18%	19%	20%	18%	18%	46%	61%	61%	62%	63%	66%	51%	49%
Fluvastatin	4%	2%	2%	4%	4%	2%	1%	1%	1%	1%	1%	1%	0%
Lovastatin	30%	18%	12%	6%	4%	2%	1%	1%	1%	0%	0%	0%	0%
Pitavastatin	0%	0%	1%	7%	9%	7%	4%	4%	4%	4%	6%	5%	5%
Pravastatin	11%	8%	6%	5%	4%	4%	3%	3%	3%	2%	2%	2%	1%
Rosuvastatin	0%	2%	7%	9%	8%	7%	7%	9%	8%	8%	8%	33%	36%
Simvastatin	37%	50%	52%	49%	50%	31%	20%	18%	16%	14%	9%	5%	3%
<b>Combination</b>	<b>0%</b>	<b>0%</b>	<b>1%</b>	<b>2%</b>	<b>3%</b>	<b>2%</b>	<b>3%</b>	<b>3%</b>	<b>5%</b>	<b>6%</b>	<b>5%</b>	<b>4%</b>	<b>5%</b>
<b>Intensity</b>													
Low	43%	25%	17%	11%	9%	6%	5%	5%	5%	5%	5%	3%	3%
Moderate	57%	75%	83%	88%	90%	94%	94%	94%	93%	93%	93%	92%	92%
High	0%	0%	0%	0%	1%	1%	1%	2%	2%	2%	2%	4%	5%
<b>Institution</b>													
Primary	63%	61%	59%	59%	58%	58%	56%	56%	56%	57%	56%	58%	58%
Secondary	20%	23%	25%	26%	26%	25%	27%	28%	28%	28%	29%	29%	29%
Tertiary	14%	13%	13%	14%	14%	13%	14%	13%	14%	13%	12%	11%	11%
Others	3%	2%	2%	2%	3%	3%	4%	3%	3%	2%	2%	2%	2%

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47









Figure 1. Statin prescriptions by institution and intensity a) all; b) primary-; c) secondary-; and d) tertiary healthcare institutions








Figure 2. Prescribing rates of selected statins among new statin users

**Table 3. Associations between disease history and prescription of moderated- or high-intensity statins**

	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015
History of hypertension	1.04	1.16	1.04	0.92	1.01	0.98	1.09	1.04	1.02	1.05	1.20
	0.94-1.15	1.03-1.29	0.92-1.18	0.80-1.07	0.87-1.18	0.84-1.14	0.94-1.26	0.90-1.20	0.87-1.19	0.88-1.24	1.00-1.44
History of diabetes	1.12	1.15	0.99	0.94	0.75	0.82	0.78	0.78	0.92	0.83	0.92
	1.01-1.24	1.03-1.29	0.88-1.12	0.81-1.09	0.64-0.87	0.70-0.96	0.68-0.91	0.67-0.91	0.78-1.08	0.69-0.99	0.76-1.11
History of DoA	1.00	0.99	1.01	1.01	1.02	1.08	0.98	1.08	1.10	1.02	1.03
	0.87-1.15	0.86-1.14	0.87-1.18	0.85-1.20	0.85-1.21	0.91-1.30	0.83-1.17	0.91-1.31	0.91-1.34	0.82-1.25	0.82-1.30
History of CeVD	1.18	1.20	0.84	0.83	0.69	0.88	0.70	0.85	0.80	0.72	0.77
	1.00-1.38	1.01-1.42	0.71-0.99	0.69-1.01	0.57-0.83	0.71-1.08	0.58-0.84	0.70-1.04	0.65-0.98	0.58-0.90	0.60-0.98
History of IHD	1.41	1.26	1.04	1.02	0.76	0.75	0.94	0.88	1.01	1.06	0.92
	1.24-1.60	1.09-1.44	0.90-1.21	0.85-1.22	0.64-0.91	0.63-0.90	0.78-1.13	0.73-1.06	0.82-1.23	0.85-1.33	0.72-1.18

Table 4. Results of segmented regression analysis of interrupted time series method

	Total			Primary care			Secondary care			Tertiary care		
	Coefficient	Standard error	p-value	Coefficient	Standard error	p-value	Coefficient	Standard error	p-value	Coefficient	Standard error	p-value
<b>Atorvastatin (2003-2009)</b>												
$\beta_0$ :Intercept	2611.9	168.5	< 0.001	850.3	46.4	< 0.001	1109.8	102.7	< 0.005	651.8	38.7	< 0.001
$\beta_1$ :Time	221.5	50.8	< 0.05	75.1	14.0	< 0.05	108.2	32.5	< 0.05	38.2	11.7	< 0.05
$\beta_2$ :Generic	3236.1	232.8	< 0.001	2846.7	64.1	< 0.0001	373.2	148.8	0.087	16.2	53.5	0.78
$\beta_3$ :Time:Generic	2687.5	232.8	< 0.05	1597.9	64.1	< 0.0001	736.8	148.8	< 0.05	352.8	53.5	< 0.01
<b>Rosuvastatin (2004-2015)</b>												
$\beta_0$ :Intercept	1376.5	141.9	< 0.001	295.7	29.1	< 0.001	655.9	59.0	< 0.001	424.9	61.8	< 0.0001
$\beta_1$ :Time	76.1	22.9	< 0.05	13.5	4.7	< 0.05	42.8	9.5	< 0.005	19.8	10.0	0.08
$\beta_2$ :Generic	3687.5	251.6	< 0.0001	3163.3	51.6	< 0.0001	517.1	104.5	< 0.0051	7.1	109.6	0.95
$\beta_3$ :Time:Generic	2453.9	294.7	< 0.0001	177.5	60.4	< 0.05	2243.2	122.4	< 0.0001	33.2	128.4	0.80

Notes:  $\beta_0$  is the pre period intercept;  $\beta_1$  is the pre period slope (baseline time trend);  $\beta_2$  is the immediate effect of the event on the intercept;  $\beta_3$  is the slope change after the event;

### Appendix 1. Drug code of statins in Korea

Drug Names	ATC code	National Code system (Strength (mg) and code)	
Atorvastatin	C10AA05	10	111501ATB
		20	111502ATB
		40	111503ATB
		80	111504ATB
Fluvastatin	C10AA04	20	162401ACH
		40	162402ACH
		80	162403ATR
Lovastatin	C10AA02	20	185801ATB
Pitavastatin	C10AA08	1	470902ATB
		2	470901ATB
		4	470903ATB
Pravastatin	C10AA03	5	216602ATB
		10	216601ATB
		20	216603ATB
		40	216604ATB
Rosuvastatin	C10AA07	5	454003ATB
		10	454001ATB
		20	454002ATB
Simvastatin	C10AA01	5	227805ATB
		10	227803ATB
		20	227801ATB, 227801ATR
		40	227802ATB
		80	227806ATB
Ezetimibe and atorvastatin	C10BA05	10 + 10	633800ATB
		10 + 20	633900ATB
		10 + 40	634800ATB
Ezetimibe and rosuvastatin	C10BA06	10 + 5	640700ATB
		10 + 10	640800ATB
		10 + 20	640900ATB
Ezetimibe and simvastatin	C10BA02	10 + 10	471000ATB
		10 + 20	471100ATB
Fenofibrate and simvastatin	C10BA04	145 + 20	631400ATB
		145 + 40	631500ATB

ATC: anatomical therapeutic chemical

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

# BMJ Open

## Patterns of statin utilization for new users and market dynamics in South Korea: A 13-year Retrospective Cohort Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026603.R1
Article Type:	Research
Date Submitted by the Author:	13-Dec-2018
Complete List of Authors:	Son, Kyung-Bok; Ewha Womans University, Bae, SeungJin; Ewha Womans University, College of Pharmacy
<b>Primary Subject Heading</b>:	Public health
Secondary Subject Heading:	Pharmacology and therapeutics
Keywords:	statins, statin utilization, a retrospective study, South Korea

SCHOLARONE™  
Manuscripts

# Patterns of statin utilization for new users and market dynamics in South Korea: A 13-year Retrospective Cohort

## Study

a) Kyung-Bok Son, b) SeungJin Bae (Corresponding author)

a) College of Pharmacy, Ewha Womans University, Seoul, South Korea

Tel) +82-2-3277-5927, sonkyungbok@gmail.com

b) College of Pharmacy, Ewha Womans University, Seoul, South Korea

Tel) +82-2-3277-3056, sjbae@ewha.ac.kr

College of Pharmacy, Ewha Womans University, Seoul, South Korea

52 Ewhayeodae-gil, Seodaemun-gu, Seoul, 03760, Korea

Tel) +82-2-3277-3056, Fax) +82-2-3277-4599

sjbae@ewha.ac.kr

# Patterns of statin utilization for new users and market dynamics in South Korea: A 13-year Retrospective Cohort

## Study

Objective: This study analyzed utilization of statins for new statin users and assessed market dynamics of statins in South Korea.

Design: This study is a retrospective cohort study.

Setting: The yearly claims data for statins were retrieved from the National Health Insurance Service-National Sample Cohort.

Main outcome measure: We are interested in new statin users during 2003-2015 in Korea.

Information on prescribed statins, including intensity of statins and entry of new and follow-on statins in the market, and health care institutions that prescribed the statins were also collected. In time series analysis, we estimated the effect of introduction of generics in the market, specifically for newly prescribed statin users.

Results: This 13-year longitudinal study of a sample cohort provided by the NHIS found that the incidence of new statin user increase from 838.1/100,000 persons in 2003 to 1626.9/100,000 persons in 2015. Most new users were initiated on a monotherapy that was prescribed at primary healthcare



1  
2  
3  
4 institutions. However, the statin market for new users were quite dynamic in Korea. Firstly, the most  
5  
6  
7 commonly prescribed statin changed several times during the study period. Secondly, the use of  
8  
9  
10 moderate-intensity statins increased from 57% in 2003 to 92% in 2015. In line with this result, we  
11  
12  
13 could not observe substantial differences in prescription of statins in groups having selected  
14  
15  
16 diseases history. Lastly, we found market invasion or switch of statins among new statin users,  
17  
18  
19 specifically at primary healthcare institutions.

20  
21  
22 Conclusion: Similar to other countries, the incidence of new statin users has been increased in Korea.  
23  
24  
25 However, the statin market in Korea is quite dynamic compared to other countries. Interestingly,  
26  
27  
28 discounted price of originals after the introduction of generics immediately expand markets or  
29  
30  
31 substitute the market particularly in primary healthcare institutions in Korea.

### 32 33 34 35 36 Strengths and limitations of this study

37  
38  
39  
40  
41  
42 Given the market size of statins and a number of "me-too" drugs and generic statins, statin  
43  
44  
45 utilization, including switching drugs, in health systems has been the subject of considerable interest.

46  
47  
48  
49  
50  
51  
52 The National Health Insurance Service-National Sample Cohort (NHIS-NSC), a population-based  
53  
54  
55 cohort, provides public health researchers useful information regarding utilization of health services.

1  
2  
3  
4  
5  
6  
7  
8 This 13-year longitudinal study of a sample cohort presented that the incidence of new statin user  
9  
10  
11 increase from 838.1/100,000 persons in 2003 to 1626.9/100,000 persons in 2015.  
12  
13  
14  
15  
16  
17

18 Patterns of prescription and market dynamics of statins found in this study is quite different from  
19  
20  
21 other studies in different regions.  
22  
23  
24  
25  
26  
27

28 Interestingly, discounted price of originals after the introduction of generics immediately expand  
29  
30  
31 markets or substitute the market particularly in primary healthcare institutions in Korea.  
32  
33  
34  
35  
36  
37  
38  
39

#### 40 A funding statement:

41  
42 This research received no specific grant from any funding agency in the public, commercial or not-  
43  
44  
45 for-profit sectors.  
46  
47  
48  
49  
50

#### 51 A competing interests statement

52  
53 Non-financial and any similar financial associations that may be relevant to the submitted  
54  
55  
56 manuscript.  
57  
58  
59  
60

## Introduction

Cardiovascular diseases (CVDs) account for 31% of all global deaths, taking the lives of 17.7 million people annually <sup>1</sup>. Similarly, CVDs are among the leading causes of death in South Korea (hereafter Korea) <sup>2,3</sup>. Hypercholesterolemia is a well-established, but modifiable risk factor for CVDs <sup>4-8</sup>. Lifestyle changes and several types of medications have been recommended to control blood lipid levels. Among the medications, statins are a major drug class that functions in reducing low-density lipoprotein cholesterol (LDL-C) <sup>9-16</sup>. Specifically, statins are recommended by several clinical guidelines, including the American College of Cardiology/American Heart Association (ACC/AHA) Guideline <sup>10</sup>, the European Society of Cardiology (ESC) <sup>16</sup>, and the UK's National Institute for Health and Care Excellence Guideline <sup>11</sup>, as the drug of choice for reduction of blood lipids to prevent CVDs.

In recent decades, statins have been the most commonly prescribed drugs in the world, and their global market sales reached approximately 28.5 billion dollars in 2014 <sup>17</sup>. Studies from several countries reported substantial increases in prescription rates of statins, including increased daily doses of statins <sup>18-22</sup>. Likewise, drug expenditure for statins has increased from 496 billion won in 2010 to 786 billion won in 2016 in Korea <sup>2,3</sup>. It should also be noted that there are many "me-too" drugs, including generics or follow on drugs, under the statin category <sup>12</sup>. For example, atorvastatin,

1  
2  
3  
4 fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin, as well as a number of  
5  
6  
7 generics, are now available for hypercholesterolemia patients in the Korean market.  
8  
9

10  
11  
12  
13  
14 Given the market size of statins and a number of "me-too" drugs and generic statins, statin  
15  
16  
17 utilization, including switching drugs, in health systems has been the subject of considerable interest  
18  
19  
20 in the perspective of clinical pharmacy and public health <sup>23-29</sup>. For instance, several European  
21  
22  
23 countries have restricted the prescribing of patented statins when generic statins became available  
24  
25  
26 at a much lower cost <sup>30,31</sup>. However, notably few studies have dealt empirically with the issue or  
27  
28  
29 included real-world data with statin users, especially in Korea. Meanwhile, it was reported that drug  
30  
31  
32 switching among statin users is low in Korea <sup>2</sup>. Therefore, we selected new statin users to understand  
33  
34  
35 statin utilization and market dynamics of statins in Korea. Given the limited drug switching among  
36  
37  
38 statin users, analysing statin utilization of new users could be used as an important resource to  
39  
40  
41 evaluate the use of statins and to assess market dynamics of statins in Korea.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

This study analysed the utilization of statins for new statin users and assessed the market dynamics  
of statins. Specifically, this study examined characteristics of new statin users and the prescribing of  
statin drugs over the last thirteen years, investigated the association between medical history of  
patients and intensity of statins, and analysed market dynamics of statins, including market

1  
2  
3  
4 penetration and switching among new statin users.  
5  
6  
7  
8  
9  
10

## 11 Methods

### 12 Data source

13  
14  
15  
16 This study used the National Health Insurance Service-National Sample Cohort (NHIS-NSC), a  
17 population-based cohort established by the National Health Insurance Service <sup>32</sup>. The dataset is  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
This dataset is comprised of approximately 1 million individuals (approximately 2% of the population) selected randomly from South Koreans. The NHIS built a target population of 46,605,433 individuals in 2002, and then 1,025,340 participants was randomly selected from the target population. Specifically, systematic stratified random sampling with proportional allocation within each stratum was conducted to construct the cohort <sup>32</sup>.

The cohort dataset consists of four databases on participants' insurance eligibility, medical treatments, health care institutions, and general health examinations for the period from January 1, 2002, to December 31, 2015 <sup>32</sup>. The dataset provides information on demographic and socioeconomic characteristics, such as age, gender, and level of income. Income level was calculated based on the insurance premium that participant pays. Also, patients' disease diagnosis was coded based on the International Classification of Diseases-10th Revision (ICD-10), and the corresponding

1  
2  
3  
4 medical expenditure such as medical and prescription information are available. The prescription  
5  
6  
7 information covers the date and duration of the prescription, the prescribed drugs' international  
8  
9  
10 nonproprietary names (INN), dosage, the route of administration, prescribers' specialty and the  
11  
12  
13 types of the healthcare institution.  
14  
15  
16  
17  
18  
19

## 20 Study design

21  
22 This study is interested in new statin users. New statin users were defined as those who had not  
23  
24  
25 been prescribed any statin in the year prior to the date of the first statin prescription observed in  
26  
27  
28 the cohort dataset <sup>33</sup>. Therefore, new statin users in each year from 2003 to 2015 were included in  
29  
30  
31 the study population of each year. Specifically, the first prescription for outpatients that included  
32  
33  
34 any statin was set as an index date and analysed in the study.  
35  
36  
37  
38  
39

40 The studied drugs include the statins atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin,  
41  
42  
43 rosuvastatin, and simvastatin. The information of individual drugs marketed in Korea are stated in  
44  
45  
46 Appendix 1. In this study, we defined mono-therapy as only one statin prescription, while we defined  
47  
48  
49 combination therapy as prescription for a statin plus other lipid-lowering drugs, including fibrates  
50  
51  
52 or ezetimibe. In addition, we searched the market of statins in Korea, including the entry of new  
53  
54  
55 drugs and follow on drugs and their pricing information on the website of the Ministry of Food and  
56  
57  
58  
59  
60

1  
2  
3  
4 Drug Safety (MFDS)<sup>1</sup> and the Health Insurance Review and Assessment Service (HIRA)<sup>2</sup>, respectively.  
5  
6

7 In Korea, co-payment for medicines that prescribed for outpatients are 30% of total expenditure,  
8  
9 including pharmacy preparation charge, thus financial burden is less likely to influence the statin  
10  
11 adherence, unlike previous study <sup>34</sup>.  
12  
13  
14  
15  
16  
17  
18  
19

20 Statins were grouped into three levels of intensity <sup>10,35</sup>: high-intensity statins; moderate-intensity  
21  
22 statins; and low-intensity statins. Daily doses can be calculated from the prescription data. High-  
23  
24 intensity statins include atorvastatin  $\geq 40$  mg/day, rosuvastatin  $\geq 20$  mg/day and simvastatin  $\geq 80$   
25  
26 mg/day. Low-intensity statins include atorvastatin  $< 10$  mg/day, rosuvastatin  $< 5$  mg/day, simvastatin  
27  
28  $< 20$  mg/day, pravastatin  $< 40$  mg/day, lovastatin  $< 40$  mg/day, pitavastatin  $< 2$  mg/day and fluvastatin  
29  
30  $< 80$  mg/day. Lastly, moderate-intensity statins include 10 mg/day  $\leq$  atorvastatin  $< 40$  mg/day, 5  
31  
32 mg/day  $\leq$  rosuvastatin  $< 20$  mg/day, 20 mg/day  $\leq$  simvastatin  $< 80$  mg/day, pravastatin  $\geq 40$  mg/day,  
33  
34 lovastatin  $\geq 40$  mg/day, pitavastatin  $\geq 2$  mg/day and fluvastatin  $\geq 80$  mg/day.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 All new statin users were classified based on their disease history, including hypertension (I10-I15),  
47  
48  
49

50  
51 \_\_\_\_\_  
52 <sup>1</sup> available at [http://drug.mfds.go.kr/html/search\\_total\\_download\\_itemPermit.jsp](http://drug.mfds.go.kr/html/search_total_download_itemPermit.jsp)  
53

54 <sup>2</sup> available at  
55 [https://biz.hira.or.kr/popup.ndo?formname=qya\\_bizcom%3A%3AInfoBank.xfdl&framename=InfoBank](https://biz.hira.or.kr/popup.ndo?formname=qya_bizcom%3A%3AInfoBank.xfdl&framename=InfoBank)  
56  
57 nk  
58  
59  
60

1  
2  
3  
4 diabetes (E10-E14), diseases of arteries, arterioles and capillaries (I70-I79), ischemic heart disease  
5  
6  
7 (I20-I25), cerebrovascular diseases (I60-I69), chronic obstructive pulmonary disease (J44), heart  
8  
9  
10 failure (I50), chronic kidney diseases (N17-N19), and atrial fibrillation (I48). Disease history was  
11  
12  
13 identified by the ICD-10 codes. Among these diseases, diabetes, diseases of arteries, arterioles and  
14  
15  
16 capillaries, cerebrovascular diseases, and heart failure are related to the use of statins for CVD  
17  
18  
19 prevention <sup>14,15,36-38</sup>. Individuals were identified as having a disease history of the specific disease if  
20  
21  
22 they had a primary diagnosis that corresponded to each diagnosis within three years prior to the  
23  
24  
25 first prescription date <sup>38,39</sup>.

26  
27  
28  
29  
30  
31  
32 Lastly, to investigate the association between the providers' characteristics and the intensity of the  
33  
34  
35 statin prescribed, we sorted medical institutions by primary-, secondary-, and tertiary institutions.  
36  
37  
38 Primary care institutions include clinic-level medical institutions that provide medical services to  
39  
40  
41 outpatients. Secondary care institutions include hospital-level medical institutions that provide  
42  
43  
44 health services primarily to inpatients. Tertiary care institutions include superior general hospitals,  
45  
46  
47 designated by the Minister of Health and Welfare, that provide medical service requiring high level  
48  
49  
50 of expertise for treating serious disease.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



#### Data analysis

This study used descriptive statistics to examine characteristics of new statin users and prescribed statin drugs, employed the  $\chi^2$  test to investigate the associations between certain disease history and prescription of moderate- or high-intensity statins, and applied interrupted time series analysis to understand the market dynamics of statins. In time series analysis, we estimated the effect of the introduction of generics on the market, specifically for newly prescribed statin users<sup>40</sup>. We presented the result of simple linear regression before and after the introduction of generics<sup>41</sup>

$$Y_t = \beta_0 + \beta_1 T + \beta_2 X_t + \beta_3 TX_t$$

$Y_t$ : the number of new users that prescribed the certain statin at time  $t$

$T$ : the time elapsed since the start of the study

$X_t$ : a dummy variable indicating the pre-intervention period or the post-intervention period

It should be noted that we defined the intervention year as the year when the price of originals were discounted due to the entry of follow on drugs. Generally speaking, the price of originals was

1  
2  
3  
4 discounted as soon as the entry of the follow on drugs, in case of atorvastatin that occurred in  
5  
6  
7 2008. However, the price reduction of original rosuvastatin was deferred until 2014 for the reason  
8  
9  
10 of valid patent that original rosuvastatin has until 2014, even though the follow on drugs were  
11  
12  
13 available in 2008. Therefore, we used the year of 2008 and 2014 as the intervention year of the  
14  
15  
16 model for atorvastatin and rosuvastatin, respectively. Data management and analysis were  
17  
18  
19 performed using the R statistical software (version 3.4.1). P-values under 0.05 were considered to  
20  
21  
22 be significance.  
23  
24  
25  
26  
27  
28

#### 29 Ethical statement

30  
31 This study used a de-identified secondary dataset. Therefore, it was exempted from review by the  
32  
33  
34 Institutional Review Board (IRB) of Ewha Womans University (IRB No. 158-10).  
35  
36  
37  
38  
39

#### 40 Patient and public involvement

41  
42 No patients were involved in developing the research question, outcome measure, and design of  
43  
44  
45 the study. We are unable to disseminate the results of the research directly to study participants.  
46  
47  
48

## 49 Results

### 50 Characteristics of new statin users over time

51  
52  
53 Table 1 presents characteristics of new statin users over time. Incidence of new statin user increase  
54  
55  
56 from 838.1/100,000 persons in 2003 to 1626.9/100,000 persons in 2015. There have been more  
57  
58  
59  
60

1  
2  
3  
4 female new users than male new users, while the portion of female new statin users steadily declined  
5  
6  
7 from 56.5% in 2003 to 50.4% in 2015. During this period, the average age of new statin users with  
8  
9  
10 standard deviation remained steady (54.31 – 56.52 years old with 11.82 – 12.89 standard deviations).  
11  
12  
13 We also sorted new statin users by their income quintile. The portion of the first quintile (the lowest  
14  
15  
16 income) increased from 13% in 2003 to 16% in 2015, while the portion of the fifth quintile (the  
17  
18  
19 highest income) decreased from 33% in 2003 to 30% in 2015. In 2003, hypertension accounted for  
20  
21  
22 the highest portion of comorbidities (55%), followed by diabetes (37%), ischemic heart disease (21%),  
23  
24  
25 diseases of arteries, arterioles and capillaries (14%), and cerebrovascular diseases (12%). These  
26  
27  
28 trends remained steady in 2015.  
29  
30  
31  
32  
33  
34

#### 35 Characteristics of prescribed statin drugs among new statin users

36  
37 Table 2 shows characteristics of prescribed statin drugs among new statin users. The majority of  
38  
39  
40 patients were prescribed with a single statin (monotherapy) when they started hypercholesterolemia  
41  
42  
43 treatment, while few new users were prescribed combination therapy during the study period.  
44  
45  
46  
47  
48  
49

50 The market for monotherapy statins is dynamic. In 2003, simvastatin (37%) was the most prescribed  
51  
52  
53 statin, followed by lovastatin (30%) and atorvastatin (18%). The market share of simvastatin had  
54  
55  
56 been the highest in the market from 2003 (37%) to 2007 (50%). During this period, the market share  
57  
58  
59  
60

1  
2  
3  
4 of atorvastatin was steady (18-20%), while the market share of lovastatin decreased from 30% in  
5  
6  
7 2003 to 4% in 2007. Similarly, the market share of simvastatin decreased after 2008, while the  
8  
9  
10 market share of atorvastatin increased and maintained the highest from 46% in 2008 to 66% in  
11  
12  
13 2013. Lastly, the market share of rosuvastatin increased from 8% in 2013 to 36% in 2015, while that  
14  
15  
16 of atorvastatin decreased from 66% to 49% during the same period. In 2015, statins for new users  
17  
18  
19 were an oligopoly market: atorvastatin (49%) was the most prescribed statin, followed by  
20  
21  
22 rosuvastatin (36%).  
23  
24  
25  
26  
27  
28

29 In 2003, the prescription rates of low-intensity and moderate-intensity statins were 43% and 57%,  
30  
31 respectively. However, the prescription rate of moderate-intensity statins consistently increased to  
32  
33  
34 92% in 2015, while the prescription rate of low-intensity statins decreased to 3% in 2015. In addition,  
35  
36  
37 the use of high-intensity statins steadily increased during the study period. We also examined health  
38  
39  
40 care institutions that prescribed statins. In 2003, 63% of new statin users were prescribed at primary  
41  
42  
43 healthcare institutions followed by secondary- (20%) and tertiary care institutions (14%). During the  
44  
45  
46 study period, the portion of new users prescribed at primary and tertiary healthcare institutions  
47  
48  
49 decreased, while the portion of new users prescribed at secondary healthcare institutions increased.  
50  
51  
52 In 2015, 58% of new statin users were prescribed at primary healthcare institutions followed by  
53  
54  
55 secondary- (29%) and tertiary healthcare institutions (11%).  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8 Figure 1 shows statin prescription by health care institutions and the intensity of prescribed statins.

9  
10 The first graph in Figure 1 presents overall patterns of the prescription rates of low-, moderate-,  
11 and high-intensity statins in all institution types. The remaining graphs indicate patterns of  
12 prescription rates in primary-, secondary-, and tertiary healthcare institutions. We found that  
13 prescription rates of moderate-intensity statins were high in primary healthcare institutions, while  
14 those of high-intensity statins were high in tertiary care institutions. It is interesting to note that  
15 prescription rates of moderate-intensity statins in primary-, secondary-, and tertiary healthcare  
16 institutions in 2003 was 48%, 69%, and 78%, respectively. However, prescription rates of moderate-  
17 intensity statins reversed in primary, secondary, and tertiary healthcare institutions in 2015: 95%,  
18 90%, and 84%, respectively.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 Figure 2 presents prescription rates of selected statins, including atorvastatin, rosuvastatin, and  
42 simvastatin, during the study period. The first graph in Figure 2 shows market shares of selected  
43 statins among new statin users. Two points are noteworthy in the perspective of market dynamics.  
44 The first market dynamic occurred during 2007-2009. Specifically, atorvastatin penetrated the market  
45 of simvastatin in this period. Similarly, the second market dynamic occurred during 2013-2015.  
46 Rosuvastatin penetrated market of atorvastatin in this period. The remaining graphs present new  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 statin users of selected statins by primary-, secondary-, and tertiary- healthcare institutions. In this  
5  
6  
7 figure, we conclude that the majority of market switching of statins among new statin users occurred  
8  
9  
10 immediately at primary healthcare institutions.  
11  
12  
13  
14  
15  
16

17 Table 3 indicates the associations between certain disease histories and the prescription of  
18  
19 moderate- or high-intensity statins. Interestingly, no substantial differences in the prescription of  
20  
21  
22  
23 statins were observed through the study period in groups with histories of diseases of arteries,  
24  
25  
26 arterioles and capillaries. Furthermore, patients with history of diabetes, cerebrovascular diseases,  
27  
28  
29 and ischemic heart disease were less likely to be prescribed moderate- or high-intensity statins in  
30  
31  
32 several selected years. For instance, odds ratios were calculated at 0.78 and ranged from 0.67 to  
33  
34  
35 0.91 with 95% confidence interval in 2012 for patients with diabetes.  
36  
37  
38  
39  
40  
41  
42

#### 43 Interrupted time series analysis

44 Table 4 presents results of segmented regression analysis using the interrupted time series method:  
45  
46  
47  $\beta_0$  is the pre period intercept;  $\beta_1$  is the pre period slope (baseline time trend);  $\beta_2$  is the immediate  
48  
49  
50 effect of the event on the intercept; and  $\beta_3$  is the slope change after the event. In the case of  
51  
52  
53 atorvastatin, the immediate effect of marketing generics was 3,236 new users ( $p < 0.001$ ), and the  
54  
55  
56 growth rate was increased by 2,687 new users per year ( $p < 0.005$ ) compared with previous trends.  
57  
58  
59  
60

1  
2  
3  
4 Similar trends were found in the case of rosuvastatin.  
5  
6  
7  
8  
9

## 10 11 12 Discussions 13 14 15

16 This 13-year longitudinal study of a sample cohort provided by the NHIS found that incidence of  
17 new statin user increase from 838.1/100,000 persons in 2003 to 1626.9/100,000 persons in 2015.  
18  
19

20 Most new users were initiated on a monotherapy that was prescribed at primary healthcare  
21 institutions. In addition, the use of moderate-intensity statins increased, notably at primary  
22 healthcare institutions. Specifically, the prescription rate of moderate-intensity statins at primary  
23 healthcare institutions was low (48%) in 2003. However, the figure was doubled in 2015 (95%).  
24  
25  
26  
27  
28  
29  
30  
31  
32

33 The characteristics of new statin users and health care institutions that prescribed statins were  
34 similar to other studies that investigated prescription patterns of all statin users in Korea <sup>2,3</sup>. It is  
35 noteworthy to compare the results of statin prescription for new users with other countries <sup>33,42-45</sup>:  
36 statin market for new users is quite dynamic in Korea.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51 First, the most commonly used statin changed several times during the study period in Korea, while  
52 atorvastatin has been the most prescribed statin during 2002-2011 in Taiwan <sup>33</sup>. For instance,  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 simvastatin had the highest prescription rate until 2007, while atorvastatin had the highest  
5  
6  
7 prescription rate after 2008. It should be noted that generics of atorvastatin were available with  
8  
9  
10 discounted prices compared to the originals of the previous year (approximately 68%) in 2008, and  
11  
12  
13 the price of the originals was discounted approximately 20% compared to the previous year. We  
14  
15  
16 could find similar results in the case of rosuvastatin. Generics of rosuvastatin were available in 2010  
17  
18  
19 and the prices of generics were 0.41 \$<sup>3</sup>, 0.61 \$, and 0.81 \$ for a single tablet of 5 mg, and 10 mg,  
20  
21  
22 and 20 mg, respectively, which account for approximately 68% of the original counterparts. In such  
23  
24  
25 a case of the introduction of generics, the prices of originals would be decreased to 80% compared  
26  
27  
28 to the previous year. However, price reduction was deferred until 2014 in this case for the reason  
29  
30  
31 of valid patent that original rosuvastatin has until 2014. In the end, the price of original rosuvastatin  
32  
33  
34 decreased to approximately 80% compared to that of the previous year in 2014. It is interesting to  
35  
36  
37 note the prescription rates of rosuvastatin: the market share of rosuvastatin in 2009 was 7% and  
38  
39  
40 slightly increased 9% in 2010 when generics with discounted prices (approximately 32%) were  
41  
42  
43 marketed, and later increased 33% in 2014 when prices of the original were discounted  
44  
45  
46 (approximately 20%). It means that the sole introduction of generics is not quite effective in  
47  
48  
49 expanding the market in Korea. However, discounted price of the original after the introduction of  
50  
51  
52 generics was related with the market expansion.  
53  
54  
55

---

56  
57 <sup>3</sup> Exchange rate is 1,100 won / dollar  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8 Interestingly, patterns of prescription found in this study is quite different from other studies in  
9  
10 different regions. For instance, the incidence of new treatments decreased for atorvastatin and  
11  
12 increased for simvastatin in Italia, Denmark, and Spain <sup>46-48</sup>. Specifically, the market share of statin  
13  
14 for new users in Southern Italian primary care was in the order of simvastatin (34%), atorvastatin  
15  
16 (26.6%), and rosuvastatin (15.4%) <sup>48</sup>. Furthermore, the vast majority of new users were started  
17  
18 treatments with simvastatin in Northern Denmark from 2004 to 2010 <sup>47</sup>. However, in Korea  
19  
20 simvastatin has been losing market share since 2008 and the current market share of simvastatin is  
21  
22 marginal (3%) in 2015.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

35 Second, the portion of moderate-intensity statins was high in Korea. For instance, the portion of  
36  
37 low-, moderate-, and high-intensity statins among new statin users in Korea was 5%, 93%, and 2%  
38  
39 in 2011. However, the portion of low-, moderate-, and high-intensity statins in Taiwan was 27%,  
40  
41 71%, and 2% in the same year. Lastly, the portion of low-, moderate-, and high-intensity statins in  
42  
43 Spain was 4%, 72%, and 24% from 2006 to 2010. Given these findings, we could conclude that  
44  
45 Korean general practitioners or specialists frequently prescribes moderate-intensity statins. In line  
46  
47 with this result, we found no substantial differences in the prescription of moderate- or high-  
48  
49 intensity statins in groups with histories of hypertension, diabetes, diseases of arteries, arterioles  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 and capillaries, cerebrovascular diseases, and ischemic heart disease in Korea.  
5  
6  
7  
8  
9

10  
11 Korean guidelines for the management of dyslipidemia states that the first goal is LDL-C<sup>49</sup>. Statin  
12 is the first-choice drug for the treatment of hypercholesterolemia (class of recommendation I, level  
13 of evidence A) because it has a relatively low risk profile and proven effects of decreasing CVD by  
14 lowering LDL-C. *"Statins should be prescribed"* and the dose adjusted to reach the LDL-C target  
15 level for high-risk and very high-risk groups (I, A), whereas *"statin use should be considered"* if  
16 LDL-C is not reduced to the first target even after lifestyle modification for weeks or months (IIa,  
17 B). The guidelines also provide dosage and administration of statins: lovastatin 20-80 mg/day,  
18 pravastatin 10-40 mg/day, simvastatin 20-40 mg/day, fluvastatin 20-80 mg/day, atorvastatin 10-80  
19 mg/day, rosuvastatin 5-20mg/day, and pitavastatin 1-4 mg/day. Interestingly, atorvastatin and  
20 rosuvastatin, the top-2 best-selling statins in Korea, was recommended as moderate- and high-  
21 intensity dosage.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

In addition, we found that the pricing and marketing strategies of manufacturers might encourage  
physicians to prescribe moderate- and high-intensity statins. For instance, the manufacturer  
discounted the price of simvastatin 40 mg (approximately 34%) in 2003, and the price was the same  
as simvastatin 20 mg. Likewise, the other manufacturer that produce atorvastatin utilized the same

1  
2  
3  
4 strategy: the manufacturer discounted the price of atorvastatin 40 mg (35%) in 2003, and the price  
5  
6  
7 was the same as atorvastatin 20 mg; and the manufacturer discounted the price of atorvastatin 20  
8  
9  
10 mg (30%) in 2007, which was the same price as atorvastatin 10 mg. In addition, the manufacturer  
11  
12  
13 marketed atorvastatin 80 mg in the market to preempt the high-strength statins market in 2008.  
14  
15  
16  
17  
18  
19

20 Third, we found market expansion when price of original statins were discounted. It is interesting  
21  
22  
23 to analyse market expansion by health care institutions. In cases of atorvastatin and rosuvastatin,  
24  
25  
26 the immediate effect of the event was large in primary healthcare institutions. For instance, the  
27  
28  
29 immediate effect of marketing generics of rosuvastatin was 3,163 users ( $p < 0.0000$ ) and 517 users  
30  
31  
32 ( $p < 0.005$ ) in primary- and secondary- healthcare institutions, respectively. However, the immediate  
33  
34  
35 effect of the event in tertiary care institutions was marginal and insignificant: 16.2 ( $p = 0.78$ ) for  
36  
37  
38 atorvastatin and 7.1 ( $p = 0.95$ ) for rosuvastatin. These results demonstrate that the discounted price  
39  
40  
41 of originals after the introduction of generics immediately expands markets, particularly in primary  
42  
43  
44 healthcare institutions. However, the growth rates, sorted by health care institutions, after the event  
45  
46  
47 vary according to drugs. For instance, the growth rate of atorvastatin was in the order of primary-,  
48  
49  
50 secondary-, and tertiary healthcare institutions, 1,597 ( $p < 0.0001$ ), 736 ( $p < 0.05$ ), and 352 ( $p < 0.001$ ),  
51  
52  
53 respectively, while that of simvastatin was in the order of secondary-, primary-, and tertiary  
54  
55  
56 healthcare institutions, 2,243 ( $p < 0.0001$ ), 178 ( $p < 0.05$ ), and 33 ( $p = 0.80$ ), respectively,  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8 This study notably analysed the utilization of statins for new statin users and assessed the market  
9  
10 dynamics of statins over the last thirteen years with a real-world dataset provided by the NHIS.  
11  
12 However, this study has several limitations. First, this study used claims data that does not contain  
13  
14 information on biochemical test data of patients, such as LDL cholesterol level. It means that we  
15  
16 could not assess prescription patterns by disease severity. In addition, the claims data does not  
17  
18 contain information on whether the prescribed drugs were originals or generics. Therefore, further  
19  
20 research is needed to assess the impact of generics on the market, including the contribution to  
21  
22 market expansion by originals and generics, respectively. Second, this study used sample data and  
23  
24 assumed that the data is to be representative, yet attention should be paid when generalize our  
25  
26 results. Lastly, this study only used the first prescription that included any statins. Therefore, switches  
27  
28 among statins were not included in the study. However, it would be reasonable to assume that  
29  
30 switches among statins would be low in the Korean market <sup>2</sup>.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

## 47 Conclusions

48  
49 Similar to other countries, the incidence of new statin users has been increased in Korea. However,  
50  
51 the statin market in Korea is quite dynamic compared to other countries. It is noteworthy that the  
52  
53 portion of new statin users that were prescribed moderate intensity statins has increased during  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 the study period. In addition, no substantial differences in the prescriptions of statins were observed  
5  
6  
7 in groups with selected disease histories. Interestingly, discounted price of originals after the  
8  
9  
10 introduction of generics immediately expand markets or substitute the market particularly in primary  
11  
12  
13 healthcare institutions in Korea.

14  
15  
16  
17  
18  
19 **Contributors** KS designed the study, collected and analyzed data, wrote, and revised the manuscript.  
20  
21  
22 SB wrote the draft and revised the paper for important intellectual content. All authors read and  
23  
24  
25 approved the final manuscript.  
26  
27  
28  
29  
30  
31

32  
33 **Funding** None declared.  
34  
35

36  
37 **Competing interests** None declared.  
38  
39

40  
41 **Patient consent** Not required.  
42

43  
44 **Data sharing statement:** No additional data are available.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1. Characteristics of new statin users over time**

	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015
<b>Incidence (100,000 person)</b>	838.1	893.2	1118.2	1256.4	1277.4	1341.7	1532.3	1497.8	1472.4	1508.4	1463.5	1640.3	1626.9
<b>Sex</b>													
Female	56.5%	55.0%	56.8%	55.8%	54.8%	54.3%	55.2%	54.6%	53.2%	53.1%	52.0%	50.7%	50.4%
<b>Age</b>													
Mean	54.40	54.31	55.15	55.61	55.62	55.48	55.61	55.71	55.58	55.65	55.57	56.52	55.90
SD	11.82	12.00	12.15	12.47	12.68	12.52	12.51	12.39	12.46	12.71	12.89	12.79	12.75
<b>Income level (the quintile)</b>													
The first	13%	14%	15%	15%	15%	14%	15%	15%	15%	15%	16%	16%	16%
The second	13%	13%	12%	14%	13%	14%	14%	15%	15%	15%	14%	15%	15%
The third	17%	17%	18%	16%	18%	18%	18%	17%	18%	17%	17%	17%	17%
The fourth	24%	23%	22%	23%	23%	23%	23%	23%	22%	22%	23%	22%	22%
The fifth	33%	32%	33%	32%	32%	31%	30%	31%	30%	30%	30%	30%	30%
<b>Comorbidities</b>													
Hypertension	N/A	55%	59%	58%	58%	56%	54%	53%	53%	52%	52%	48%	
Diabetes		37%	39%	40%	39%	37%	36%	36%	37%	38%	41%	39%	
DoA		14%	17%	20%	24%	25%	25%	23%	22%	21%	22%	20%	
IHD		21%	22%	22%	21%	19%	19%	19%	18%	17%	18%	16%	
CeVD		12%	13%	15%	15%	15%	15%	14%	15%	15%	14%	14%	
COPD		5%	6%	6%	6%	5%	5%	5%	5%	5%	5%	4%	
Heart failure		5%	4%	4%	4%	3%	4%	4%	4%	4%	4%	4%	
CKD		2%	2%	2%	2%	2%	2%	2%	2%	2%	3%	3%	3%
Afib		2%	2%	2%	3%	2%	2%	2%	2%	2%	2%	3%	2%

1 Notes: DoA: diseases of arteries, arterioles and capillaries; IHD: ischemic heart disease; CeVD: cerebrovascular diseases; COPD: chronic obstructive pulmonary disease;  
2 CKD: chronic kidney diseases; and Afib: atrial fibrillation  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

For peer review only

**Table 2. Characteristics of prescribed statin drugs among new statin users**

	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015
Number of new statin users	8,205	8,835	11,181	12,564	12,774	13,333	15,139	14,713	14,374	14,639	14,117	15,731	15,514
<b>Monotherapy</b>	<b>100%</b>	<b>100%</b>	<b>99%</b>	<b>98%</b>	<b>97%</b>	<b>98%</b>	<b>97%</b>	<b>97%</b>	<b>95%</b>	<b>94%</b>	<b>95%</b>	<b>96%</b>	<b>95%</b>
Atorvastatin	18%	19%	20%	18%	18%	46%	61%	61%	62%	63%	66%	51%	49%
Fluvastatin	4%	2%	2%	4%	4%	2%	1%	1%	1%	1%	1%	1%	0%
Lovastatin	30%	18%	12%	6%	4%	2%	1%	1%	1%	0%	0%	0%	0%
Pitavastatin	0%	0%	1%	7%	9%	7%	4%	4%	4%	4%	6%	5%	5%
Pravastatin	11%	8%	6%	5%	4%	4%	3%	3%	3%	2%	2%	2%	1%
Rosuvastatin	0%	2%	7%	9%	8%	7%	7%	9%	8%	8%	8%	33%	36%
Simvastatin	37%	50%	52%	49%	50%	31%	20%	18%	16%	14%	9%	5%	3%
<b>Combination</b>	<b>0%</b>	<b>0%</b>	<b>1%</b>	<b>2%</b>	<b>3%</b>	<b>2%</b>	<b>3%</b>	<b>3%</b>	<b>5%</b>	<b>6%</b>	<b>5%</b>	<b>4%</b>	<b>5%</b>
<b>Intensity</b>													
Low	43%	25%	17%	11%	9%	6%	5%	5%	5%	5%	5%	3%	3%
Moderate	57%	75%	83%	88%	90%	94%	94%	94%	93%	93%	93%	92%	92%
High	0%	0%	0%	0%	1%	1%	1%	2%	2%	2%	2%	4%	5%
<b>Institution</b>													
Primary	63%	61%	59%	59%	58%	58%	56%	56%	56%	57%	56%	58%	58%
Secondary	20%	23%	25%	26%	26%	25%	27%	28%	28%	28%	29%	29%	29%
Tertiary	14%	13%	13%	14%	14%	13%	14%	13%	14%	13%	12%	11%	11%
Others	3%	2%	2%	2%	3%	3%	4%	3%	3%	2%	2%	2%	2%



**Table 3. Associations between disease history and prescription of moderated- or high-intensity statins**

	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015
History of hypertension	1.04	1.16	1.04	0.92	1.01	0.98	1.09	1.04	1.02	1.05	1.20
	0.94-1.15	1.03-1.29	0.92-1.18	0.80-1.07	0.87-1.18	0.84-1.14	0.94-1.26	0.90-1.20	0.87-1.19	0.88-1.24	1.00-1.44
History of diabetes	1.12	1.15	0.99	0.94	0.75	0.82	0.78	0.78	0.92	0.83	0.92
	1.01-1.24	1.03-1.29	0.88-1.12	0.81-1.09	0.64-0.87	0.70-0.96	0.68-0.91	0.67-0.91	0.78-1.08	0.69-0.99	0.76-1.11
History of DoA	1.00	0.99	1.01	1.01	1.02	1.08	0.98	1.08	1.10	1.02	1.03
	0.87-1.15	0.86-1.14	0.87-1.18	0.85-1.20	0.85-1.21	0.91-1.30	0.83-1.17	0.91-1.31	0.91-1.34	0.82-1.25	0.82-1.30
History of CeVD	1.18	1.20	0.84	0.83	0.69	0.88	0.70	0.85	0.80	0.72	0.77
	1.00-1.38	1.01-1.42	0.71-0.99	0.69-1.01	0.57-0.83	0.71-1.08	0.58-0.84	0.70-1.04	0.65-0.98	0.58-0.90	0.60-0.98
History of IHD	1.41	1.26	1.04	1.02	0.76	0.75	0.94	0.88	1.01	1.06	0.92
	1.24-1.60	1.09-1.44	0.90-1.21	0.85-1.22	0.64-0.91	0.63-0.90	0.78-1.13	0.73-1.06	0.82-1.23	0.85-1.33	0.72-1.18

Notes: DoA: diseases of arteries, arterioles and capillaries; IHD: ischemic heart disease; CeVD: cerebrovascular diseases;

Table 4. Results of segmented regression analysis of interrupted time series method

	Total			Primary care			Secondary care			Tertiary care		
	Coefficient	Standard error	p-value	Coefficient	Standard error	p-value	Coefficient	Standard error	p-value	Coefficient	Standard error	p-value
<b>Atorvastatin (2003-2009)</b>												
$\beta_0$ :Intercept	2611.9	168.5	< 0.001	850.3	46.4	< 0.001	1109.8	102.7	< 0.005	651.8	38.7	< 0.001
$\beta_1$ :Time	221.5	50.8	< 0.05	75.1	14.0	< 0.05	108.2	32.5	< 0.05	38.2	11.7	< 0.05
$\beta_2$ :Generic	3236.1	232.8	< 0.001	2846.7	64.1	< 0.0001	373.2	148.8	0.087	16.2	53.5	0.78
$\beta_3$ :Time:Generic	2687.5	232.8	< 0.05	1597.9	64.1	< 0.0001	736.8	148.8	< 0.05	352.8	53.5	< 0.01
<b>Rosuvastatin (2004-2015)</b>												
$\beta_0$ :Intercept	1376.5	141.9	< 0.001	295.7	29.1	< 0.001	655.9	59.0	< 0.001	424.9	61.8	< 0.0001
$\beta_1$ :Time	76.1	22.9	< 0.05	13.5	4.7	< 0.05	42.8	9.5	< 0.005	19.8	10.0	0.08
$\beta_2$ :Generic	3687.5	251.6	< 0.0001	3163.3	51.6	< 0.0001	517.1	104.5	< 0.0051	7.1	109.6	0.95
$\beta_3$ :Time:Generic	2453.9	294.7	< 0.0001	177.5	60.4	< 0.05	2243.2	122.4	< 0.0001	33.2	128.4	0.80

Notes:  $\beta_0$  is the pre period intercept;  $\beta_1$  is the pre period slope (baseline time trend);  $\beta_2$  is the immediate effect of the event on the intercept;  $\beta_3$  is the slope change after the event;

1  
2  
3  
4 Figure 1. Statin prescriptions by institution and intensity a) all; b) primary-; c) secondary-; and d)  
5 tertiary healthcare institutions  
6  
7  
8  
9

10 Figure 2. Prescribing rates of selected statins among new statin users  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only





## References

1. WHO. Cardiovascular diseases (CVDs). 2016; [http://www.who.int/cardiovascular\\_diseases/en/](http://www.who.int/cardiovascular_diseases/en/). Accessed 10 Aug, 2018.
2. Hye-Jae L, Tae-Jin L. Impact of Price Control on Drug Expenditure and Factors Associated with the Drug Switch among Statins: Analysis of HIRA-NPS Data. *Health Policy and Management (HPM)*. 2013;23(2):112-123.
3. Shin S, Song H, Jang S, Sung Y. Development of the outcome index of hyperlipidemia treatments (lipid lowering agents). *Seoul: Health Insurance Review and Assessment Service*. 2009.
4. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. *Journal of the American College of Cardiology*. 2004;44(3):720-732.
5. Sharrett AR, Ballantyne C, Coady S, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein (a), apolipoproteins AI and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. *Circulation*. 2001;104(10):1108-1113.
6. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. *Circulation*. 1998;97(18):1837-1847.
7. Lee KH, Jeong MH, Ahn Y, Cho MC, Kim CJ, Kim YJ. New horizons of acute myocardial infarction: from the Korea Acute Myocardial Infarction Registry. *Journal of Korean medical science*. 2013;28(2):173-180.
8. Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. *The Lancet*. 1999;353(9147):89-92.
9. Prevention EAfC, Rehabilitation, Reiner Z, et al. ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *Eur Heart J*. 2011;32(14):1769-1818.
10. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology*. 2014;63(25 Part B):2889-2934.
11. NICE Clinical Guideline 181. *Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease 2014*. London: National Clinical Guideline Centre;2014.
12. Weng TC, Yang YHK, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- equivalence of statins. *Journal of clinical pharmacy and therapeutics*. 2010;35(2):139-151.
13. Pedersen T, Kjekshus J, Berg K, et al. Randomized trial of cholesterol-lowering in 4444 patients with coronary-heart-disease-the Scandinavian Simvastatin Survival Study (4s). *Lancet*. 1994;344(8934):1383-1389.
14. Group HPSC. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. *The Lancet*. 2002;360(9326):7-22.
15. Collins R, Armitage J, Parish S, Sleight P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. *Lancet (London, England)*. 2003;361(9374):2005-2016.
16. Reiner Ž, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *European heart journal*. 2011;32(14):1769-1818.
17. IMS Institute for Healthcare Informatics. *Top 20 global therapy areas 2014*. England and Wales: IMS Health MIDAS;2014.
18. IMS Institute for Healthcare Informatics. *The global use of medicines: outlook through 2016*. IMS Institute for Healthcare Informatics;2012.
19. Godman B, Shrank W, Andersen M, et al. Policies to enhance prescribing efficiency in Europe: findings and future implications. *Frontiers in pharmacology*. 2011;1:141.
20. Leporowski A, Godman B, Kurdi A, et al. Ongoing activities to optimize the quality and efficiency of lipid-lowering agents in the Scottish national health service: influence and implications. *Expert review of pharmacoeconomics & outcomes research*. 2018;18(6):655-666.
21. Woerkom Mv, Piepenbrink H, Godman B, et al. Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. *Journal of comparative effectiveness research*. 2012;1(6):527-538.
22. Fraeyman J, Van Hal G, Godman B, Beutels P. The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium. *Expert review of pharmacoeconomics & outcomes research*. 2013;13(1):141-151.
23. Stargardt T. The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany. *The European Journal of Health Economics*. 2010;11(3):267-277.
24. Ahn E, Shin DW, Yang H-k, et al. Treatment gap in the national health-screening program in Korea: claim-based follow-up of statin use for sustained Hypercholesterolemia. *Journal of Korean medical science*. 2015;30(9):1266-1272.
25. Kwon H-Y, Godman B. Do newly marketed generic medicines expand markets using





- descriptive time series analysis and mixed logit models? Korea as an exemplar and its implications. *BMC health services research*. 2016;16(1):130.
26. Sakshaug S, Furu K, Karlstad Ø, Rønning M, Skurtveit S. Switching statins in Norway after new reimbursement policy—a nationwide prescription study. *British journal of clinical pharmacology*. 2007;64(4):476-481.
27. Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. *International journal of clinical practice*. 2008;62(3):480-484.
28. Health Insurance Review and Assessment Service. *The results of clinical effectiveness and cost-effectiveness of hyperlipidemia treatments*. Seoul: Health Insurance Review and Assessment Service;2009.
29. Germany Federal Joint Committee. *Explanatory statements on the grouping of statins*. Federal Joint Committee;2004.
30. Martikainen JE, Saastamoinen LK, Korhonen MJ, Enlund H, Helin-Salmivaara A. Impact of restricted reimbursement on the use of statins in Finland: a register-based study. *Medical care*. 2010:761-766.
31. Godman B, Burkhardt T, Bucsecs A, Wettermark B, Wieninger P. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future. *Expert review of pharmacoeconomics & outcomes research*. 2009;9(5):475-484.
32. Lee J, Lee JS, Park S-H, Shin SA, Kim K. Cohort profile: the national health insurance service—national sample cohort (NHIS-NSC), South Korea. *International journal of epidemiology*. 2016;46(2):e15-e15.
33. Hsieh HC, Hsu JC, Lu CY. 10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan's National Health Insurance Research Database. *BMJ open*. 2017;7(5):e014150.
34. Simoens S, Sinnaeve PR. Patient co-payment and adherence to statins: a review and case studies. *Cardiovascular drugs and therapy*. 2014;28(1):99-109.
35. Rosenson RS, Kent ST, Brown TM, et al. Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease. *Journal of the American College of Cardiology*. 2015;65(3):270-277.
36. Finegold JA, Manisty CH, Goldacre B, Barron AJ, Francis DP. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. *European journal of preventive cardiology*. 2014;21(4):464-474.
37. Alberton M, Wu P, Druyts E, Briel M, Mills E. Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. *QJM: An International Journal of Medicine*. 2011;105(2):145-157.
38. Lo Re III V, Haynes K, Goldberg D, et al. Validity of diagnostic codes to identify cases of

- 1  
2  
3  
4  
5 severe acute liver injury in the US Food and Drug Administration's Mini-Sentinel Distributed  
6 Database. *Pharmacoepidemiology and drug safety*. 2013;22(8):861-872.
- 7  
8 39. Chen GL, Hsiao FY, Dong YH, Shen LJ, Wu FLL. Statins and the risk of liver injury: a  
9 population-based case-control study. *Pharmacoepidemiology and drug safety*.  
10 2014;23(7):719-725.
- 11  
12 40. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of  
13 interrupted time series studies in medication use research. *Journal of clinical pharmacy and*  
14 *therapeutics*. 2002;27(4):299-309.
- 15  
16 41. Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of  
17 public health interventions: a tutorial. *International Journal of Epidemiology*. 2017;46(1):348-  
18 355.
- 19  
20 42. Walley T, Folino-Gallo P, Stephens P, Van Ganse E, Group E. Trends in prescribing and  
21 utilization of statins and other lipid lowering drugs across Europe 1997–2003. *British journal*  
22 *of clinical pharmacology*. 2005;60(5):543-551.
- 23  
24 43. Ferrajolo C, Arcoraci V, Sullo MG, et al. Pattern of statin use in southern Italian primary care:  
25 can prescription databases be used for monitoring long-term adherence to the treatment?  
26 *PloS one*. 2014;9(7):e102146.
- 27  
28 44. Svensson E, Nielsen RB, Hasvold P, Aarskog P, Thomsen RW. Statin prescription patterns,  
29 adherence, and attainment of cholesterol treatment goals in routine clinical care: a Danish  
30 population-based study. *Clinical epidemiology*. 2015;7:213.
- 31  
32 45. O'Keeffe AG, Nazareth I, Petersen I. Time trends in the prescription of statins for the primary  
33 prevention of cardiovascular disease in the United Kingdom: a cohort study using The Health  
34 Improvement Network primary care data. *Clinical epidemiology*. 2016;8:123.
- 35  
36 46. García-Gil M, Blanch J, Comas-Cufí M, et al. Patterns of statin use and cholesterol goal  
37 attainment in a high-risk cardiovascular population: A retrospective study of primary care  
38 electronic medical records. *Journal of Clinical Lipidology*. 2016;10(1):134-142.
- 39  
40 47. Svensson E, Nielsen RB, Hasvold P, Aarskog P, Thomsen RW. Statin prescription patterns,  
41 adherence, and attainment of cholesterol treatment goals in routine clinical care: a Danish  
42 population-based study. *Clin Epidemiol*. 2015;7:213-223.
- 43  
44 48. Ferrajolo C, Arcoraci V, Sullo MG, et al. Pattern of Statin Use in Southern Italian Primary  
45 Care: Can Prescription Databases Be Used for Monitoring Long-Term Adherence to the  
46 Treatment? *PLOS ONE*. 2014;9(7):e102146.
- 47  
48 49. Kim CJ, Kim J, Kim KI, et al. 2015 Korean guidelines for the management of dyslipidemia:  
49 executive summary (English translation). *Korean circulation journal*. 2016;46(3):275-306.
- 50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46





## Appendix 1. Drug code of statins in Korea

Drug Names	ATC code	National Code System (Strength and code)		The date of drug entry	
				New drug	First follow on drug
Atorvastatin	C10AA05	10	111501ATB	1999.08.01	2007.01.17
		20	111502ATB		
		40	111503ATB		
		80	111504ATB		
Fluvastatin	C10AA04	20	162401ACH	1994.10.10	N/A
		40	162402ACH		
		80	162403ATR		
Lovastatin	C10AA02	20	185801ATB	1997.08.06	1997.12.11
Pitavastatin	C10AA08	1	470902ATB	2005.01.06	2011.05.24
		2	470901ATB		
		4	470903ATB		
Pravastatin	C10AA03	5	216602ATB	1990.04.10	1994.05.17
		10	216601ATB		
		20	216603ATB		
		40	216604ATB		
Rosuvastatin	C10AA07	5	454003ATB	2002.01.15	2008.11.07
		10	454001ATB		
		20	454002ATB		
Simvastatin	C10AA01	5	227805ATB	1996.08.01	2002.07.09
		10	227803ATB		
		20	227801ATB, 227801ATR		
		40	227802ATB		
		80	227806ATB		
Ezetimibe and atorvastatin	C10BA05	10 + 10	633800ATB		
		10 + 20	633900ATB		
		10 + 40	634800ATB		
Ezetimibe and rosuvastatin	C10BA06	10 + 5	640700ATB		
		10 + 10	640800ATB		
		10 + 20	640900ATB		
Ezetimibe and simvastatin	C10BA02	10 + 10	471000ATB		
		10 + 20	471100ATB		
Fenofibrate and simvastatin	C10BA04	145 + 20	631400ATB		
		145 + 40	631500ATB		

ATC: anatomical therapeutic chemical

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Page #	Recommendation
<b>Title and abstract</b>	1	2	(a) Indicate the study's design with a commonly used term in the title or the abstract
		2	(b) Provide in the abstract an informative and balanced summary of what was done and what was found
<b>Introduction</b>			
Background/rationale	2	7	Explain the scientific background and rationale for the investigation being reported
Objectives	3	7	State specific objectives, including any prespecified hypotheses
<b>Methods</b>			
Study design	4	9-11	Present key elements of study design early in the paper
Setting	5	8-9	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	9-11	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up
		N/A	(b) For matched studies, give matching criteria and number of exposed and unexposed
Variables	7	9-13	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*	9-11	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	N/A	Describe any efforts to address potential sources of bias
Study size	10	N/A	Explain how the study size was arrived at
Quantitative variables	11	9-13	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	9-13	(a) Describe all statistical methods, including those used to control for confounding
		N/A	(b) Describe any methods used to examine subgroups and interactions
		N/A	(c) Explain how missing data were addressed
		N/A	(d) If applicable, explain how loss to follow-up was addressed
		N/A	(e) Describe any sensitivity analyses
<b>Results</b>			
Participants	13*	13-14	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed
		13-14	(b) Give reasons for non-participation at each stage

		N/A	(c) Consider use of a flow diagram
Descriptive data	14*	14-17	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders
		N/A	(b) Indicate number of participants with missing data for each variable of interest
		N/A	(c) Summarise follow-up time (eg, average and total amount)
Outcome data	15*	13-14	Report numbers of outcome events or summary measures over time
Main results	16	13-17	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included
		N/A	(b) Report category boundaries when continuous variables were categorized
		N/A	(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	N/A	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
<b>Discussion</b>			
Key results	18	18	Summarise key results with reference to study objectives
Limitations	19	22-23	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	18-23	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	22-23	Discuss the generalisability (external validity) of the study results
<b>Other information</b>			
Funding	22	24	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

# BMJ Open

## Patterns of statin utilization for new users and market dynamics in South Korea: A 13-year Retrospective Cohort Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026603.R2
Article Type:	Research
Date Submitted by the Author:	16-Jan-2019
Complete List of Authors:	Son, Kyung-Bok; Ewha Womans University, Bae, SeungJin; Ewha Womans University, College of Pharmacy
<b>Primary Subject Heading</b>:	Public health
Secondary Subject Heading:	Pharmacology and therapeutics
Keywords:	statins, statin utilization, a retrospective study, South Korea

SCHOLARONE™  
Manuscripts

# Patterns of statin utilization for new users and market dynamics in South Korea: A 13-year Retrospective Cohort

## Study

a) Kyung-Bok Son, b) SeungJin Bae (Corresponding author)

a) College of Pharmacy, Ewha Womans University, Seoul, South Korea

Tel) +82-2-3277-5927, sonkyungbok@gmail.com

b) College of Pharmacy, Ewha Womans University, Seoul, South Korea

Tel) +82-2-3277-3056, sjbae@ewha.ac.kr

College of Pharmacy, Ewha Womans University, Seoul, South Korea

52 Ewhayeodae-gil, Seodaemun-gu, Seoul, 03760, Korea

Tel) +82-2-3277-3056, Fax) +82-2-3277-4599

sjbae@ewha.ac.kr

# Patterns of statin utilization for new users and market dynamics in South Korea: A 13-year Retrospective Cohort

## Study

Objective: This study analyzed utilization of statins for new statin users and assessed market dynamics of statins in South Korea.

Design: This study is a retrospective cohort study.

Setting: The yearly claims data for statins were retrieved from the National Health Insurance Service-National Sample Cohort.

Main outcome measure: We are interested in new statin users during 2003-2015 in Korea.

Information on prescribed statins, including intensity of statins and entry of new and follow-on statins in the market, and health care institutions that prescribed the statins were also collected. In time series analysis, we estimated the effect of introduction of generics in the market, specifically for newly prescribed statin users.

Results: This 13-year longitudinal study of a sample cohort provided by the NHIS found that the incidence of new statin user increase from 838.1/100,000 persons in 2003 to 1626.9/100,000 persons in 2015. Most new users were initiated on a monotherapy that was prescribed at primary healthcare

1  
2  
3  
4 institutions. However, the statin market for new users were quite dynamic in Korea. Firstly, the most  
5  
6  
7 commonly prescribed statin changed several times during the study period. Secondly, the use of  
8  
9  
10 moderate-intensity statins increased from 57% in 2003 to 92% in 2015. In line with this result, we  
11  
12  
13 could not observe substantial differences in prescription of statins in groups having selected  
14  
15  
16 diseases history. Lastly, we found market invasion or switch of statins among new statin users,  
17  
18  
19 specifically at primary healthcare institutions.

20  
21  
22 Conclusion: Similar to other countries, the incidence of new statin users has been increased in Korea.  
23  
24  
25 However, the statin market in Korea is quite dynamic compared to other countries. Interestingly,  
26  
27  
28 discounted price of originals after the introduction of generics immediately expand markets or  
29  
30  
31 substitute the market particularly in primary healthcare institutions in Korea.

### 32 33 34 35 36 Strengths and limitations of this study

37  
38  
39  
40  
41  
42 Given the market size of statins and a number of "me-too" drugs and generic statins, statin  
43  
44  
45 utilization, including switching drugs, in health systems has been the subject of considerable interest.

46  
47  
48  
49  
50  
51  
52 The National Health Insurance Service-National Sample Cohort (NHIS-NSC), a population-based  
53  
54  
55 cohort, provides public health researchers useful information regarding utilization of health services.



1  
2  
3  
4  
5  
6  
7  
8 This 13-year longitudinal study of a sample cohort presented that the incidence of new statin user  
9  
10  
11 increase from 838.1/100,000 persons in 2003 to 1626.9/100,000 persons in 2015.  
12  
13  
14  
15  
16  
17

18 Patterns of prescription and market dynamics of statins found in this study is quite different from  
19  
20  
21 other studies in different regions.  
22  
23  
24  
25  
26  
27

28 Interestingly, discounted price of originals after the introduction of generics immediately expand  
29  
30  
31 markets or substitute the market particularly in primary healthcare institutions in Korea.  
32  
33  
34  
35  
36  
37  
38  
39

#### 40 A funding statement:

41  
42 This research received no specific grant from any funding agency in the public, commercial or not-  
43  
44  
45 for-profit sectors.  
46  
47  
48  
49  
50

#### 51 A competing interests statement

52  
53 Non-financial and any similar financial associations that may be relevant to the submitted  
54  
55  
56 manuscript.  
57  
58  
59  
60

## Introduction

Cardiovascular diseases (CVDs) account for 31% of all global deaths, taking the lives of 17.7 million people annually <sup>1</sup>. Similarly, CVDs are among the leading causes of death in South Korea (hereafter Korea) <sup>2,3</sup>. Hypercholesterolemia is a well-established, but modifiable risk factor for CVDs <sup>4-8</sup>. Lifestyle changes and several types of medications have been recommended to control blood lipid levels. Among the medications, statins are a major drug class that functions in reducing low-density lipoprotein cholesterol (LDL-C) <sup>9-16</sup>. Specifically, statins are recommended by several clinical guidelines, including the American College of Cardiology/American Heart Association (ACC/AHA) Guideline <sup>10</sup>, the European Society of Cardiology (ESC) <sup>16</sup>, and the UK's National Institute for Health and Care Excellence Guideline <sup>11</sup>, as the drug of choice for reduction of blood lipids to prevent CVDs.

In recent decades, statins have been the most commonly prescribed drugs in the world, and their global market sales reached approximately 28.5 billion dollars in 2014 <sup>17</sup>. Studies from several countries reported substantial increases in prescription rates of statins, including increased daily doses of statins <sup>18-22</sup>. Likewise, drug expenditure for statins has increased from 496 billion won in 2010 to 786 billion won in 2016 in Korea <sup>2,3</sup>. It should also be noted that there are many "me-too" drugs, including generics or follow on drugs, under the statin category <sup>12</sup>. For example, atorvastatin,

1  
2  
3  
4 fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin, as well as a number of  
5  
6  
7 generics, are now available for hypercholesterolemia patients in the Korean market.  
8  
9

10  
11  
12  
13  
14 Given the market size of statins and a number of "me-too" drugs and generic statins, statin  
15  
16  
17 utilization, including switching drugs, in health systems has been the subject of considerable interest  
18  
19  
20 in the perspective of clinical pharmacy and public health <sup>23-29</sup>. For instance, several European  
21  
22  
23 countries have restricted the prescribing of patented statins when generic statins became available  
24  
25  
26 at a much lower cost <sup>30,31</sup>. However, notably few studies have dealt empirically with the issue or  
27  
28  
29 included real-world data with statin users, especially in Korea. Meanwhile, it was reported that drug  
30  
31  
32 switching among statin users is low in Korea <sup>2</sup>. Therefore, we selected new statin users to understand  
33  
34  
35 statin utilization and market dynamics of statins in Korea. Given the limited drug switching among  
36  
37  
38 statin users, analysing statin utilization of new users could be used as an important resource to  
39  
40  
41 evaluate the use of statins and to assess market dynamics of statins in Korea.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

This study analysed the utilization of statins for new statin users and assessed the market dynamics  
of statins. Specifically, this study examined characteristics of new statin users and the prescribing of  
statin drugs over the last thirteen years, investigated the association between medical history of  
patients and intensity of statins, and analysed market dynamics of statins, including market

1  
2  
3  
4 penetration and switching among new statin users.  
5  
6  
7  
8  
9  
10

## 11 Methods

### 12 Data source

13  
14  
15  
16 This study used the National Health Insurance Service-National Sample Cohort (NHIS-NSC), a  
17 population-based cohort established by the National Health Insurance Service <sup>32</sup>. The dataset is  
18  
19 comprised of approximately 1 million individuals (approximately 2% of the population) selected  
20  
21 randomly from South Koreans. The NHIS built a target population of 46,605,433 individuals in 2002,  
22  
23 and then 1,025,340 participants was randomly selected from the target population. Specifically,  
24  
25 systematic stratified random sampling with proportional allocation within each stratum was  
26  
27 conducted to construct the cohort <sup>32</sup>.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 The cohort dataset consists of four databases on participants' insurance eligibility, medical  
42  
43 treatments, health care institutions, and general health examinations for the period from January 1,  
44  
45 2002, to December 31, 2015 <sup>32</sup>. The dataset provides information on demographic and  
46  
47 socioeconomic characteristics, such as age, gender, and level of income. Income level was calculated  
48  
49 based on the insurance premium that participant pays. Also, patients' disease diagnosis was coded  
50  
51 based on the International Classification of Diseases-10th Revision (ICD-10), and the corresponding  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 medical expenditure such as medical and prescription information are available. The prescription  
5  
6  
7 information covers the date and duration of the prescription, the prescribed drugs' international  
8  
9  
10 nonproprietary names (INN), dosage, the route of administration, prescribers' specialty and the  
11  
12  
13 types of the healthcare institution.  
14  
15  
16  
17  
18  
19

## 20 Study design

21  
22 This study is interested in new statin users. New statin users were defined as those who had not  
23  
24  
25 been prescribed any statin in the year prior to the date of the first statin prescription observed in  
26  
27  
28 the cohort dataset <sup>33</sup>. Therefore, new statin users in each year from 2003 to 2015 were included in  
29  
30  
31 the study population of each year. Specifically, the first prescription for outpatients that included  
32  
33  
34 any statin was set as an index date and analysed in the study.  
35  
36  
37  
38  
39

40 The studied drugs include the statins atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin,  
41  
42  
43 rosuvastatin, and simvastatin. The information of individual drugs marketed in Korea are stated in  
44  
45  
46 Appendix 1. In this study, we defined mono-therapy as only one statin prescription, while we defined  
47  
48  
49 combination therapy as prescription for a statin plus other lipid-lowering drugs, including fibrates  
50  
51  
52 or ezetimibe. In addition, we searched the market of statins in Korea, including the entry of new  
53  
54  
55 drugs and follow on drugs and their pricing information on the website of the Ministry of Food and  
56  
57  
58  
59  
60

1  
2  
3  
4 Drug Safety (MFDS)<sup>1</sup> and the Health Insurance Review and Assessment Service (HIRA)<sup>2</sup>, respectively.  
5  
6

7 In Korea, co-payment for medicines that prescribed for outpatients are 30% of total expenditure,  
8  
9 including pharmacy preparation charge, thus financial burden is less likely to influence the statin  
10  
11 adherence, unlike previous study <sup>34</sup>.  
12  
13  
14  
15  
16  
17  
18  
19

20 Statins were grouped into three levels of intensity <sup>10,35</sup>: high-intensity statins; moderate-intensity  
21  
22 statins; and low-intensity statins. Daily doses can be calculated from the prescription data. High-  
23  
24 intensity statins include atorvastatin 40–80 mg/day, rosuvastatin 20–40 mg/day and simvastatin 80  
25  
26 mg/day. Low-intensity statins include simvastatin 10 mg/day, pravastatin 10–20 mg/day, lovastatin  
27  
28 20 mg/day, pitavastatin 1mg/day and fluvastatin 20–40 mg/day. Lastly, moderate-intensity statins  
29  
30 include atorvastatin 10–20 mg/day, rosuvastatin 5–10 mg/day, simvastatin 20–40 mg/ day,  
31  
32 pravastatin 40–80 mg/day, lovastatin 40 mg/day, pitavastatin 2–4 mg/day and fluvastatin 80  
33  
34 mg/day.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 All new statin users were classified based on their disease history, including hypertension (I10-I15),  
47  
48  
49

50  
51 \_\_\_\_\_  
52 <sup>1</sup> available at [http://drug.mfds.go.kr/html/search\\_total\\_download\\_itemPermit.jsp](http://drug.mfds.go.kr/html/search_total_download_itemPermit.jsp)

53 <sup>2</sup> available at  
54 [https://biz.hira.or.kr/popup.ndo?formname=qya\\_bizcom%3A%3AInfoBank.xfdl&framename=InfoBank](https://biz.hira.or.kr/popup.ndo?formname=qya_bizcom%3A%3AInfoBank.xfdl&framename=InfoBank)  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 diabetes (E10-E14), diseases of arteries, arterioles and capillaries (I70-I79), ischemic heart disease  
5  
6  
7 (I20-I25), cerebrovascular diseases (I60-I69), chronic obstructive pulmonary disease (J44), heart  
8  
9  
10 failure (I50), chronic kidney diseases (N17-N19), and atrial fibrillation (I48). Disease history was  
11  
12  
13 identified by the ICD-10 codes. Among these diseases, diabetes, diseases of arteries, arterioles and  
14  
15  
16 capillaries, cerebrovascular diseases, and heart failure are related to the use of statins for CVD  
17  
18  
19 prevention <sup>14,15,36-38</sup>. Individuals were identified as having a disease history of the specific disease if  
20  
21  
22 they had a primary diagnosis that corresponded to each diagnosis within three years prior to the  
23  
24  
25 first prescription date <sup>38,39</sup>.

26  
27  
28  
29  
30  
31  
32 Lastly, to investigate the association between the providers' characteristics and the intensity of the  
33  
34  
35 statin prescribed, we sorted medical institutions by primary-, secondary-, and tertiary institutions.  
36  
37  
38 Primary care institutions include clinic-level medical institutions that provide medical services to  
39  
40  
41 outpatients. Secondary care institutions include hospital-level medical institutions that provide  
42  
43  
44 health services primarily to inpatients. Tertiary care institutions include superior general hospitals,  
45  
46  
47 designated by the Minister of Health and Welfare, that provide medical service requiring high level  
48  
49  
50 of expertise for treating serious disease.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

#### Data analysis

This study used descriptive statistics to examine characteristics of new statin users and prescribed statin drugs, employed the  $\chi^2$  test to investigate the associations between certain disease history and prescription of moderate- or high-intensity statins, and applied interrupted time series analysis to understand the market dynamics of statins. In time series analysis, we estimated the effect of the introduction of generics on the market, specifically for newly prescribed statin users<sup>40</sup>. We presented the result of simple linear regression before and after the introduction of generics<sup>41</sup>

$$Y_t = \beta_0 + \beta_1 T + \beta_2 X_t + \beta_3 TX_t$$

$Y_t$ : the number of new users that prescribed the certain statin at time  $t$

$T$ : the time elapsed since the start of the study

$X_t$ : a dummy variable indicating the pre-intervention period or the post-intervention period

It should be noted that we defined the intervention year as the year when the price of originals were discounted due to the entry of follow on drugs. Generally speaking, the price of originals was



1  
2  
3  
4 discounted as soon as the entry of the follow on drugs, in case of atorvastatin that occurred in  
5  
6  
7 2008. However, the price reduction of original rosuvastatin was deferred until 2014 for the reason  
8  
9  
10 of valid patent that original rosuvastatin has until 2014, even though the follow on drugs were  
11  
12  
13 available in 2008. Therefore, we used the year of 2008 and 2014 as the intervention year of the  
14  
15  
16 model for atorvastatin and rosuvastatin, respectively. Data management and analysis were  
17  
18  
19 performed using the R statistical software (version 3.4.1). P-values under 0.05 were considered to  
20  
21  
22 be significance.  
23  
24  
25  
26  
27  
28

#### 29 Ethical statement

30  
31 This study used a de-identified secondary dataset. Therefore, it was exempted from review by the  
32  
33  
34 Institutional Review Board (IRB) of Ewha Womans University (IRB No. 158-10).  
35  
36  
37  
38  
39

#### 40 Patient and public involvement

41  
42 No patients were involved in developing the research question, outcome measure, and design of  
43  
44  
45 the study. We are unable to disseminate the results of the research directly to study participants.  
46  
47  
48

## 49 Results

### 50 Characteristics of new statin users over time

51  
52  
53 Table 1 presents characteristics of new statin users over time. Incidence of new statin user increase  
54  
55  
56 from 838.1/100,000 persons in 2003 to 1626.9/100,000 persons in 2015. There have been more  
57  
58  
59  
60

1  
2  
3  
4 female new users than male new users, while the portion of female new statin users steadily declined  
5  
6  
7 from 56.5% in 2003 to 50.4% in 2015. During this period, the average age of new statin users with  
8  
9  
10 standard deviation remained steady (54.31 – 56.52 years old with 11.82 – 12.89 standard deviations).  
11  
12  
13 We also sorted new statin users by their income quintile. The portion of the first quintile (the lowest  
14  
15  
16 income) increased from 13% in 2003 to 16% in 2015, while the portion of the fifth quintile (the  
17  
18  
19 highest income) decreased from 33% in 2003 to 30% in 2015. In 2003, hypertension accounted for  
20  
21  
22 the highest portion of comorbidities (55%), followed by diabetes (37%), ischemic heart disease (21%),  
23  
24  
25 diseases of arteries, arterioles and capillaries (14%), and cerebrovascular diseases (12%). These  
26  
27  
28 trends remained steady in 2015.  
29  
30  
31  
32  
33  
34

#### 35 Characteristics of prescribed statin drugs among new statin users

36  
37 Table 2 shows characteristics of prescribed statin drugs among new statin users. The majority of  
38  
39  
40 patients were prescribed with a single statin (monotherapy) when they started hypercholesterolemia  
41  
42  
43 treatment, while few new users were prescribed combination therapy during the study period.  
44  
45  
46  
47  
48  
49

50 The market for monotherapy statins is dynamic. In 2003, simvastatin (37%) was the most prescribed  
51  
52  
53 statin, followed by lovastatin (30%) and atorvastatin (18%). The market share of simvastatin had  
54  
55  
56 been the highest in the market from 2003 (37%) to 2007 (50%). During this period, the market share  
57  
58  
59  
60

1  
2  
3  
4 of atorvastatin was steady (18-20%), while the market share of lovastatin decreased from 30% in  
5  
6  
7 2003 to 4% in 2007. Similarly, the market share of simvastatin decreased after 2008, while the  
8  
9  
10 market share of atorvastatin increased and maintained the highest from 46% in 2008 to 66% in  
11  
12  
13 2013. Lastly, the market share of rosuvastatin increased from 8% in 2013 to 36% in 2015, while that  
14  
15  
16 of atorvastatin decreased from 66% to 49% during the same period. In 2015, statins for new users  
17  
18  
19 were an oligopoly market: atorvastatin (49%) was the most prescribed statin, followed by  
20  
21  
22 rosuvastatin (36%).  
23  
24  
25  
26  
27  
28

29 In 2003, the prescription rates of low-intensity and moderate-intensity statins were 43% and 57%,  
30  
31 respectively. However, the prescription rate of moderate-intensity statins consistently increased to  
32  
33  
34 92% in 2015, while the prescription rate of low-intensity statins decreased to 3% in 2015. In addition,  
35  
36  
37 the use of high-intensity statins steadily increased during the study period. We also examined health  
38  
39  
40 care institutions that prescribed statins. In 2003, 63% of new statin users were prescribed at primary  
41  
42  
43 healthcare institutions followed by secondary- (20%) and tertiary care institutions (14%). During the  
44  
45  
46 study period, the portion of new users prescribed at primary and tertiary healthcare institutions  
47  
48  
49 decreased, while the portion of new users prescribed at secondary healthcare institutions increased.  
50  
51  
52 In 2015, 58% of new statin users were prescribed at primary healthcare institutions followed by  
53  
54  
55 secondary- (29%) and tertiary healthcare institutions (11%).  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8 Figure 1 shows statin prescription by health care institutions and the intensity of prescribed statins.

9  
10  
11 The first graph in Figure 1 presents overall patterns of the prescription rates of low-, moderate-,  
12  
13 and high-intensity statins in all institution types. The remaining graphs indicate patterns of  
14  
15 prescription rates in primary-, secondary-, and tertiary healthcare institutions. We found that  
16  
17 prescription rates of moderate-intensity statins were high in primary healthcare institutions, while  
18  
19 those of high-intensity statins were high in tertiary care institutions. It is interesting to note that  
20  
21 prescription rates of moderate-intensity statins in primary-, secondary-, and tertiary healthcare  
22  
23 institutions in 2003 was 48%, 69%, and 78%, respectively. However, prescription rates of moderate-  
24  
25 intensity statins reversed in primary, secondary, and tertiary healthcare institutions in 2015: 95%,  
26  
27 90%, and 84%, respectively.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 Figure 2 presents prescription rates of selected statins, including atorvastatin, rosuvastatin, and  
42  
43 simvastatin, during the study period. The first graph in Figure 2 shows market shares of selected  
44  
45 statins among new statin users. Two points are noteworthy in the perspective of market dynamics.  
46  
47 The first market dynamic occurred during 2007-2009. Specifically, atorvastatin penetrated the market  
48  
49 of simvastatin in this period. Similarly, the second market dynamic occurred during 2013-2015.  
50  
51 Rosuvastatin penetrated market of atorvastatin in this period. The remaining graphs present new  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 statin users of selected statins by primary-, secondary-, and tertiary- healthcare institutions. In this  
5  
6  
7 figure, we conclude that the majority of market switching of statins among new statin users occurred  
8  
9  
10 immediately at primary healthcare institutions.  
11  
12  
13  
14  
15  
16

17 Table 3 indicates the associations between certain disease histories and the prescription of  
18  
19 moderate- or high-intensity statins. Interestingly, no substantial differences in the prescription of  
20  
21  
22  
23 statins were observed through the study period in groups with histories of diseases of arteries,  
24  
25 arterioles and capillaries. Furthermore, patients with history of diabetes, cerebrovascular diseases,  
26  
27 and ischemic heart disease were less likely to be prescribed moderate- or high-intensity statins in  
28  
29 several selected years. For instance, odds ratios were calculated at 0.78 and ranged from 0.67 to  
30  
31  
32  
33  
34  
35 0.91 with 95% confidence interval in 2012 for patients with diabetes.  
36  
37  
38  
39  
40  
41

#### 42 Interrupted time series analysis

43  
44 Table 4 presents results of segmented regression analysis using the interrupted time series method:  
45  
46  
47  $\beta_0$  is the pre period intercept;  $\beta_1$  is the pre period slope (baseline time trend);  $\beta_2$  is the immediate  
48  
49 effect of the event on the intercept; and  $\beta_3$  is the slope change after the event. In the case of  
50  
51 atorvastatin, the immediate effect of marketing generics was 3,236 new users ( $p < 0.001$ ), and the  
52  
53 growth rate was increased by 2,687 new users per year ( $p < 0.005$ ) compared with previous trends.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 Similar trends were found in the case of rosuvastatin.  
5  
6  
7  
8  
9

## 10 11 12 Discussions 13 14 15

16 This 13-year longitudinal study of a sample cohort provided by the NHIS found that incidence of  
17 new statin user increase from 838.1/100,000 persons in 2003 to 1626.9/100,000 persons in 2015.  
18  
19

20 Most new users were initiated on a monotherapy that was prescribed at primary healthcare  
21 institutions. In addition, the use of moderate-intensity statins increased, notably at primary  
22 healthcare institutions. Specifically, the prescription rate of moderate-intensity statins at primary  
23 healthcare institutions was low (48%) in 2003. However, the figure was doubled in 2015 (95%).  
24  
25  
26  
27  
28  
29  
30  
31  
32

33 The characteristics of new statin users and health care institutions that prescribed statins were  
34 similar to other studies that investigated prescription patterns of all statin users in Korea <sup>2,3</sup>. It is  
35 noteworthy to compare the results of statin prescription for new users with other countries <sup>33,42-45</sup>:  
36 statin market for new users is quite dynamic in Korea.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

53 First, the most commonly used statin changed several times during the study period in Korea, while  
54 atorvastatin has been the most prescribed statin during 2002-2011 in Taiwan <sup>33</sup>. For instance,  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 simvastatin had the highest prescription rate until 2007, while atorvastatin had the highest  
5  
6  
7 prescription rate after 2008. It should be noted that generics of atorvastatin were available with  
8  
9  
10 discounted prices compared to the originals of the previous year (approximately 68%) in 2008, and  
11  
12  
13 the price of the originals was discounted approximately 20% compared to the previous year. We  
14  
15  
16 could find similar results in the case of rosuvastatin. Generics of rosuvastatin were available in 2010  
17  
18  
19 and the prices of generics were 0.41 \$<sup>3</sup>, 0.61 \$, and 0.81 \$ for a single tablet of 5 mg, and 10 mg,  
20  
21  
22 and 20 mg, respectively, which account for approximately 68% of the original counterparts. In such  
23  
24  
25 a case of the introduction of generics, the prices of originals would be decreased to 80% compared  
26  
27  
28 to the previous year. However, price reduction was deferred until 2014 in this case for the reason  
29  
30  
31 of valid patent that original rosuvastatin has until 2014. In the end, the price of original rosuvastatin  
32  
33  
34 decreased to approximately 80% compared to that of the previous year in 2014. It is interesting to  
35  
36  
37 note the prescription rates of rosuvastatin: the market share of rosuvastatin in 2009 was 7% and  
38  
39  
40 slightly increased 9% in 2010 when generics with discounted prices (approximately 32%) were  
41  
42  
43 marketed, and later increased 33% in 2014 when prices of the original were discounted  
44  
45  
46 (approximately 20%). It means that the sole introduction of generics is not quite effective in  
47  
48  
49 expanding the market in Korea. However, discounted price of the original after the introduction of  
50  
51  
52 generics was related with the market expansion.

---

56  
57 <sup>3</sup> Exchange rate is 1,100 won / dollar  
58

1  
2  
3  
4  
5  
6  
7  
8 Interestingly, patterns of prescription found in this study is quite different from other studies in  
9  
10 different regions. For instance, the incidence of new treatments decreased for atorvastatin and  
11  
12 increased for simvastatin in Italia, Denmark, and Spain <sup>46-48</sup>. Specifically, the market share of statin  
13  
14 for new users in Southern Italian primary care was in the order of simvastatin (34%), atorvastatin  
15  
16 (26.6%), and rosuvastatin (15.4%) <sup>48</sup>. Furthermore, the vast majority of new users were started  
17  
18 treatments with simvastatin in Northern Denmark from 2004 to 2010 <sup>47</sup>. However, in Korea  
19  
20 simvastatin has been losing market share since 2008 and the current market share of simvastatin is  
21  
22 marginal (3%) in 2015.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

35 Second, the portion of moderate-intensity statins was high in Korea, which is not common in other  
36  
37 countries. For instance, the portion of low-, moderate-, and high-intensity statins among new statin  
38  
39 users in Korea was 5%, 93%, and 2% in 2011. However, the portion of low-, moderate-, and high-  
40  
41 intensity statins in Taiwan was 27%, 71%, and 2% in the same year. Lastly, the portion of low-,  
42  
43 moderate-, and high-intensity statins in Spain was 4%, 72%, and 24% from 2006 to 2010. Given  
44  
45 these findings, we could conclude that Korean general practitioners or specialists frequently  
46  
47 prescribes moderate-intensity statins. In line with this result, we found no substantial differences in  
48  
49 the prescription of moderate- or high-intensity statins in groups with histories of hypertension,  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 diabetes, diseases of arteries, arterioles and capillaries, cerebrovascular diseases, and ischemic heart  
5  
6  
7 disease in Korea.  
8  
9

10  
11  
12  
13  
14 Korean guidelines for the management of dyslipidemia states that the first goal is LDL-C <sup>49</sup>. Statin  
15  
16 is the first-choice drug for the treatment of hypercholesterolemia (class of recommendation I, level  
17  
18 of evidence A) because it has a relatively low risk profile and proven effects of decreasing CVD by  
19  
20 lowering LDL-C. *"Statins should be prescribed"* and the dose adjusted to reach the LDL-C target  
21  
22 level for high-risk and very high-risk groups (I, A), whereas *"statin use should be considered"* if  
23  
24 LDL-C is not reduced to the first target even after lifestyle modification for weeks or months (IIa,  
25  
26 B). The guidelines also provide dosage and administration of statins: lovastatin 20-80 mg/day,  
27  
28 pravastatin 10-40 mg/day, simvastatin 20-40 mg/day, fluvastatin 20-80 mg/day, atorvastatin 10-80  
29  
30 mg/day, rosuvastatin 5-20mg/day, and pitavastatin 1-4 mg/day. Interestingly, atorvastatin and  
31  
32 rosuvastatin, the top-2 best-selling statins in Korea, was recommended as moderate- and high-  
33  
34 intensity dosage.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 In addition, we found that the pricing and marketing strategies of manufacturers might encourage  
51  
52 physicians to prescribe moderate- and high-intensity statins. For instance, the manufacturer  
53  
54 discounted the price of simvastatin 40 mg (approximately 34%) in 2003, and the price was the same  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 as simvastatin 20 mg. Likewise, the other manufacturer that produce atorvastatin utilized the same  
5  
6  
7 strategy: the manufacturer discounted the price of atorvastatin 40 mg (35%) in 2003, and the price  
8  
9  
10 was the same as atorvastatin 20 mg; and the manufacturer discounted the price of atorvastatin 20  
11  
12  
13 mg (30%) in 2007, which was the same price as atorvastatin 10 mg. In addition, the manufacturer  
14  
15  
16 marketed atorvastatin 80 mg in the market to preempt the high-strength statins market in 2008.  
17  
18  
19  
20  
21  
22

23 Third, we found market expansion when price of original statins were discounted. It is interesting  
24  
25 to analyse market expansion by health care institutions. In cases of atorvastatin and rosuvastatin,  
26  
27 the immediate effect of the event was large in primary healthcare institutions. For instance, the  
28  
29 immediate effect of marketing generics of rosuvastatin was 3,163 users ( $p < 0.0000$ ) and 517 users  
30  
31 ( $p < 0.005$ ) in primary- and secondary- healthcare institutions, respectively. However, the immediate  
32  
33 effect of the event in tertiary care institutions was marginal and insignificant: 16.2 ( $p = 0.78$ ) for  
34  
35 atorvastatin and 7.1 ( $p = 0.95$ ) for rosuvastatin. These results demonstrate that the discounted price  
36  
37 of originals after the introduction of generics immediately expands markets, particularly in primary  
38  
39 healthcare institutions. However, the growth rates, sorted by health care institutions, after the event  
40  
41 vary according to drugs. For instance, the growth rate of atorvastatin was in the order of primary-,  
42  
43 secondary-, and tertiary healthcare institutions, 1,597 ( $p < 0.0001$ ), 736 ( $p < 0.05$ ), and 352 ( $p < 0.001$ ),  
44  
45 respectively, while that of simvastatin was in the order of secondary-, primary-, and tertiary  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 healthcare institutions, 2,243 (p <0.0001), 178 (p <0.05), and 33 (p =0.80), respectively,  
5  
6  
7  
8  
9

10  
11 This study notably analysed the utilization of statins for new statin users and assessed the market  
12 dynamics of statins over the last thirteen years with a real-world dataset provided by the NHIS.  
13  
14

15 However, this study has several limitations. First, this study used claims data that does not contain  
16 information on biochemical test data of patients, such as LDL cholesterol level. It means that we  
17 could not assess prescription patterns by disease severity. In addition, the claims data does not  
18 contain information on whether the prescribed drugs were originals or generics. Therefore, further  
19 research is needed to assess the impact of generics on the market, including the contribution to  
20 market expansion by originals and generics, respectively. Second, this study used sample data and  
21 assumed that the data is to be representative, yet attention should be paid when generalize our  
22 results. Third, this study only used the first prescription that included any statins. Therefore, switches  
23 among statins were not included in the study. However, it would be reasonable to assume that  
24 switches among statins would be low in the Korean market <sup>2</sup>. Lastly, we noted the dosing for statins  
25 increased in Korea, and partially explained this trends with the Korean guidelines for the  
26 management of dyslipidemia and the pricing and marketing strategies of manufacturers. However,  
27 further qualitative methods are needed to understand these interesting observations.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Conclusions

Similar to other countries, the incidence of new statin users has been increased in Korea. However, the statin market in Korea is quite dynamic compared to other countries. It is noteworthy that the portion of new statin users that were prescribed moderate intensity statins has increased during the study period. In addition, no substantial differences in the prescriptions of statins were observed in groups with selected disease histories. Interestingly, discounted price of originals after the introduction of generics immediately expand markets or substitute the market particularly in primary healthcare institutions in Korea.

**Contributors** KS designed the study, collected and analyzed data, wrote, and revised the manuscript. SB revised the paper for important intellectual content. All authors read and approved the final manuscript.

**Funding** None declared.

**Competing interests** None declared.

**Patient consent** Not required.

**Data sharing statement:** No additional data are available.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**Table 1. Characteristics of new statin users over time**

	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015
<b>Incidence (100,000 person)</b>	838.1	893.2	1118.2	1256.4	1277.4	1341.7	1532.3	1497.8	1472.4	1508.4	1463.5	1640.3	1626.9
<b>Sex</b>													
Female	56.5%	55.0%	56.8%	55.8%	54.8%	54.3%	55.2%	54.6%	53.2%	53.1%	52.0%	50.7%	50.4%
<b>Age</b>													
Mean	54.40	54.31	55.15	55.61	55.62	55.48	55.61	55.71	55.58	55.65	55.57	56.52	55.90
SD	11.82	12.00	12.15	12.47	12.68	12.52	12.51	12.39	12.46	12.71	12.89	12.79	12.75
<b>Income level (the quintile)</b>													
The first	13%	14%	15%	15%	15%	14%	15%	15%	15%	15%	16%	16%	16%
The second	13%	13%	12%	14%	13%	14%	14%	15%	15%	15%	14%	15%	15%
The third	17%	17%	18%	16%	18%	18%	18%	17%	18%	17%	17%	17%	17%
The fourth	24%	23%	22%	23%	23%	23%	23%	23%	22%	22%	23%	22%	22%
The fifth	33%	32%	33%	32%	32%	31%	30%	31%	30%	30%	30%	30%	30%
<b>Comorbidities</b>													
Hypertension	N/A	55%	59%	58%	58%	56%	54%	53%	53%	52%	52%	48%	
Diabetes		37%	39%	40%	39%	37%	36%	36%	37%	38%	41%	39%	
DoA		14%	17%	20%	24%	25%	25%	23%	22%	21%	22%	20%	
IHD		21%	22%	22%	21%	19%	19%	19%	18%	17%	18%	16%	
CeVD		12%	13%	15%	15%	15%	15%	14%	15%	15%	14%	14%	
COPD		5%	6%	6%	6%	5%	5%	5%	5%	5%	5%	4%	
Heart failure		5%	4%	4%	4%	3%	4%	4%	4%	4%	4%	4%	
CKD		2%	2%	2%	2%	2%	2%	2%	2%	2%	3%	3%	3%
Afib		2%	2%	2%	3%	2%	2%	2%	2%	2%	2%	3%	2%

1 Notes: DoA: diseases of arteries, arterioles and capillaries; IHD: ischemic heart disease; CeVD: cerebrovascular diseases; COPD: chronic obstructive pulmonary disease;  
2 CKD: chronic kidney diseases; and Afib: atrial fibrillation  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

For peer review only

**Table 2. Characteristics of prescribed statin drugs among new statin users**

	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015
Number of new statin users	8,205	8,835	11,181	12,564	12,774	13,333	15,139	14,713	14,374	14,639	14,117	15,731	15,514
<b>Monotherapy</b>	<b>100%</b>	<b>100%</b>	<b>99%</b>	<b>98%</b>	<b>97%</b>	<b>98%</b>	<b>97%</b>	<b>97%</b>	<b>95%</b>	<b>94%</b>	<b>95%</b>	<b>96%</b>	<b>95%</b>
Atorvastatin	18%	19%	20%	18%	18%	46%	61%	61%	62%	63%	66%	51%	49%
Fluvastatin	4%	2%	2%	4%	4%	2%	1%	1%	1%	1%	1%	1%	0%
Lovastatin	30%	18%	12%	6%	4%	2%	1%	1%	1%	0%	0%	0%	0%
Pitavastatin	0%	0%	1%	7%	9%	7%	4%	4%	4%	4%	6%	5%	5%
Pravastatin	11%	8%	6%	5%	4%	4%	3%	3%	3%	2%	2%	2%	1%
Rosuvastatin	0%	2%	7%	9%	8%	7%	7%	9%	8%	8%	8%	33%	36%
Simvastatin	37%	50%	52%	49%	50%	31%	20%	18%	16%	14%	9%	5%	3%
<b>Combination</b>	<b>0%</b>	<b>0%</b>	<b>1%</b>	<b>2%</b>	<b>3%</b>	<b>2%</b>	<b>3%</b>	<b>3%</b>	<b>5%</b>	<b>6%</b>	<b>5%</b>	<b>4%</b>	<b>5%</b>
<b>Intensity</b>													
Low	43%	25%	17%	11%	9%	6%	5%	5%	5%	5%	5%	3%	3%
Moderate	57%	75%	83%	88%	90%	94%	94%	94%	93%	93%	93%	92%	92%
High	0%	0%	0%	0%	1%	1%	1%	2%	2%	2%	2%	4%	5%
<b>Institution</b>													
Primary	63%	61%	59%	59%	58%	58%	56%	56%	56%	57%	56%	58%	58%
Secondary	20%	23%	25%	26%	26%	25%	27%	28%	28%	28%	29%	29%	29%
Tertiary	14%	13%	13%	14%	14%	13%	14%	13%	14%	13%	12%	11%	11%
Others	3%	2%	2%	2%	3%	3%	4%	3%	3%	2%	2%	2%	2%



**Table 3. Associations between disease history and prescription of moderated- or high-intensity statins**

	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015
History of hypertension	1.04	1.16	1.04	0.92	1.01	0.98	1.09	1.04	1.02	1.05	1.20
	0.94-1.15	1.03-1.29	0.92-1.18	0.80-1.07	0.87-1.18	0.84-1.14	0.94-1.26	0.90-1.20	0.87-1.19	0.88-1.24	1.00-1.44
History of diabetes	1.12	1.15	0.99	0.94	0.75	0.82	0.78	0.78	0.92	0.83	0.92
	1.01-1.24	1.03-1.29	0.88-1.12	0.81-1.09	0.64-0.87	0.70-0.96	0.68-0.91	0.67-0.91	0.78-1.08	0.69-0.99	0.76-1.11
History of DoA	1.00	0.99	1.01	1.01	1.02	1.08	0.98	1.08	1.10	1.02	1.03
	0.87-1.15	0.86-1.14	0.87-1.18	0.85-1.20	0.85-1.21	0.91-1.30	0.83-1.17	0.91-1.31	0.91-1.34	0.82-1.25	0.82-1.30
History of CeVD	1.18	1.20	0.84	0.83	0.69	0.88	0.70	0.85	0.80	0.72	0.77
	1.00-1.38	1.01-1.42	0.71-0.99	0.69-1.01	0.57-0.83	0.71-1.08	0.58-0.84	0.70-1.04	0.65-0.98	0.58-0.90	0.60-0.98
History of IHD	1.41	1.26	1.04	1.02	0.76	0.75	0.94	0.88	1.01	1.06	0.92
	1.24-1.60	1.09-1.44	0.90-1.21	0.85-1.22	0.64-0.91	0.63-0.90	0.78-1.13	0.73-1.06	0.82-1.23	0.85-1.33	0.72-1.18

Notes: DoA: diseases of arteries, arterioles and capillaries; IHD: ischemic heart disease; CeVD: cerebrovascular diseases;

Table 4. Results of segmented regression analysis of interrupted time series method

	Total			Primary care			Secondary care			Tertiary care		
	Coefficient	Standard error	p-value	Coefficient	Standard error	p-value	Coefficient	Standard error	p-value	Coefficient	Standard error	p-value
<b>Atorvastatin (2003-2009)</b>												
$\beta_0$ :Intercept	2611.9	168.5	< 0.001	850.3	46.4	< 0.001	1109.8	102.7	< 0.005	651.8	38.7	< 0.001
$\beta_1$ :Time	221.5	50.8	< 0.05	75.1	14.0	< 0.05	108.2	32.5	< 0.05	38.2	11.7	< 0.05
$\beta_2$ :Generic	3236.1	232.8	< 0.001	2846.7	64.1	< 0.0001	373.2	148.8	0.087	16.2	53.5	0.78
$\beta_3$ :Time:Generic	2687.5	232.8	< 0.05	1597.9	64.1	< 0.0001	736.8	148.8	< 0.05	352.8	53.5	< 0.01
<b>Rosuvastatin (2004-2015)</b>												
$\beta_0$ :Intercept	1376.5	141.9	< 0.001	295.7	29.1	< 0.001	655.9	59.0	< 0.001	424.9	61.8	< 0.0001
$\beta_1$ :Time	76.1	22.9	< 0.05	13.5	4.7	< 0.05	42.8	9.5	< 0.005	19.8	10.0	0.08
$\beta_2$ :Generic	3687.5	251.6	< 0.0001	3163.3	51.6	< 0.0001	517.1	104.5	< 0.0051	7.1	109.6	0.95
$\beta_3$ :Time:Generic	2453.9	294.7	< 0.0001	177.5	60.4	< 0.05	2243.2	122.4	< 0.0001	33.2	128.4	0.80

Notes:  $\beta_0$  is the pre period intercept;  $\beta_1$  is the pre period slope (baseline time trend);  $\beta_2$  is the immediate effect of the event on the intercept;  $\beta_3$  is the slope change after the event;

1  
2  
3  
4 Figure 1. Statin prescriptions by institution and intensity a) all; b) primary-; c) secondary-; and d)  
5 tertiary healthcare institutions  
6  
7  
8  
9

10 Figure 2. Prescribing rates of selected statins among new statin users  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only





## References

1. WHO. Cardiovascular diseases (CVDs). 2016; [http://www.who.int/cardiovascular\\_diseases/en/](http://www.who.int/cardiovascular_diseases/en/). Accessed 10 Aug, 2018.
2. Hye-Jae L, Tae-Jin L. Impact of Price Control on Drug Expenditure and Factors Associated with the Drug Switch among Statins: Analysis of HIRA-NPS Data. *Health Policy and Management (HPM)*. 2013;23(2):112-123.
3. Shin S, Song H, Jang S, Sung Y. Development of the outcome index of hyperlipidemia treatments (lipid lowering agents). *Seoul: Health Insurance Review and Assessment Service*. 2009.
4. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. *Journal of the American College of Cardiology*. 2004;44(3):720-732.
5. Sharrett AR, Ballantyne C, Coady S, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein (a), apolipoproteins AI and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. *Circulation*. 2001;104(10):1108-1113.
6. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. *Circulation*. 1998;97(18):1837-1847.
7. Lee KH, Jeong MH, Ahn Y, Cho MC, Kim CJ, Kim YJ. New horizons of acute myocardial infarction: from the Korea Acute Myocardial Infarction Registry. *Journal of Korean medical science*. 2013;28(2):173-180.
8. Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. *The Lancet*. 1999;353(9147):89-92.
9. Prevention EAfC, Rehabilitation, Reiner Z, et al. ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *Eur Heart J*. 2011;32(14):1769-1818.
10. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology*. 2014;63(25 Part B):2889-2934.
11. NICE Clinical Guideline 181. *Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease 2014*. London: National Clinical Guideline Centre;2014.
12. Weng TC, Yang YHK, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic





- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- equivalence of statins. *Journal of clinical pharmacy and therapeutics*. 2010;35(2):139-151.
13. Pedersen T, Kjekshus J, Berg K, et al. Randomized trial of cholesterol-lowering in 4444 patients with coronary-heart-disease-the Scandinavian Simvastatin Survival Study (4s). *Lancet*. 1994;344(8934):1383-1389.
14. Group HPSC. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. *The Lancet*. 2002;360(9326):7-22.
15. Collins R, Armitage J, Parish S, Sleight P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. *Lancet (London, England)*. 2003;361(9374):2005-2016.
16. Reiner Ž, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *European heart journal*. 2011;32(14):1769-1818.
17. IMS Institute for Healthcare Informatics. *Top 20 global therapy areas 2014*. England and Wales: IMS Health MIDAS;2014.
18. IMS Institute for Healthcare Informatics. *The global use of medicines: outlook through 2016*. IMS Institute for Healthcare Informatics;2012.
19. Godman B, Shrank W, Andersen M, et al. Policies to enhance prescribing efficiency in Europe: findings and future implications. *Frontiers in pharmacology*. 2011;1:141.
20. Leporowski A, Godman B, Kurdi A, et al. Ongoing activities to optimize the quality and efficiency of lipid-lowering agents in the Scottish national health service: influence and implications. *Expert review of pharmacoeconomics & outcomes research*. 2018;18(6):655-666.
21. Woerkom Mv, Piepenbrink H, Godman B, et al. Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. *Journal of comparative effectiveness research*. 2012;1(6):527-538.
22. Fraeyman J, Van Hal G, Godman B, Beutels P. The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium. *Expert review of pharmacoeconomics & outcomes research*. 2013;13(1):141-151.
23. Stargardt T. The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany. *The European Journal of Health Economics*. 2010;11(3):267-277.
24. Ahn E, Shin DW, Yang H-k, et al. Treatment gap in the national health-screening program in Korea: claim-based follow-up of statin use for sustained Hypercholesterolemia. *Journal of Korean medical science*. 2015;30(9):1266-1272.
25. Kwon H-Y, Godman B. Do newly marketed generic medicines expand markets using

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- descriptive time series analysis and mixed logit models? Korea as an exemplar and its implications. *BMC health services research*. 2016;16(1):130.
26. Sakshaug S, Furu K, Karlstad Ø, Rønning M, Skurtveit S. Switching statins in Norway after new reimbursement policy—a nationwide prescription study. *British journal of clinical pharmacology*. 2007;64(4):476-481.
27. Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. *International journal of clinical practice*. 2008;62(3):480-484.
28. Health Insurance Review and Assessment Service. *The results of clinical effectiveness and cost-effectiveness of hyperlipidemia treatments*. Seoul: Health Insurance Review and Assessment Service;2009.
29. Germany Federal Joint Committee. *Explanatory statements on the grouping of statins*. Federal Joint Committee;2004.
30. Martikainen JE, Saastamoinen LK, Korhonen MJ, Enlund H, Helin-Salmivaara A. Impact of restricted reimbursement on the use of statins in Finland: a register-based study. *Medical care*. 2010:761-766.
31. Godman B, Burkhardt T, Bucsecs A, Wettermark B, Wieninger P. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future. *Expert review of pharmacoeconomics & outcomes research*. 2009;9(5):475-484.
32. Lee J, Lee JS, Park S-H, Shin SA, Kim K. Cohort profile: the national health insurance service—national sample cohort (NHIS-NSC), South Korea. *International journal of epidemiology*. 2016;46(2):e15-e15.
33. Hsieh HC, Hsu JC, Lu CY. 10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan's National Health Insurance Research Database. *BMJ open*. 2017;7(5):e014150.
34. Simoens S, Sinnaeve PR. Patient co-payment and adherence to statins: a review and case studies. *Cardiovascular drugs and therapy*. 2014;28(1):99-109.
35. Rosenson RS, Kent ST, Brown TM, et al. Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease. *Journal of the American College of Cardiology*. 2015;65(3):270-277.
36. Finegold JA, Manisty CH, Goldacre B, Barron AJ, Francis DP. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. *European journal of preventive cardiology*. 2014;21(4):464-474.
37. Alberton M, Wu P, Druyts E, Briel M, Mills E. Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. *QJM: An International Journal of Medicine*. 2011;105(2):145-157.
38. Lo Re III V, Haynes K, Goldberg D, et al. Validity of diagnostic codes to identify cases of

- 1  
2  
3  
4  
5 severe acute liver injury in the US Food and Drug Administration's Mini-Sentinel Distributed  
6 Database. *Pharmacoepidemiology and drug safety*. 2013;22(8):861-872.
- 7  
8 39. Chen GL, Hsiao FY, Dong YH, Shen LJ, Wu FLL. Statins and the risk of liver injury: a  
9 population-based case-control study. *Pharmacoepidemiology and drug safety*.  
10 2014;23(7):719-725.
- 11  
12 40. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of  
13 interrupted time series studies in medication use research. *Journal of clinical pharmacy and*  
14 *therapeutics*. 2002;27(4):299-309.
- 15  
16 41. Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of  
17 public health interventions: a tutorial. *International Journal of Epidemiology*. 2017;46(1):348-  
18 355.
- 19  
20 42. Walley T, Folino-Gallo P, Stephens P, Van Ganse E, Group E. Trends in prescribing and  
21 utilization of statins and other lipid lowering drugs across Europe 1997–2003. *British journal*  
22 *of clinical pharmacology*. 2005;60(5):543-551.
- 23  
24 43. Ferrajolo C, Arcoraci V, Sullo MG, et al. Pattern of statin use in southern Italian primary care:  
25 can prescription databases be used for monitoring long-term adherence to the treatment?  
26 *PloS one*. 2014;9(7):e102146.
- 27  
28 44. Svensson E, Nielsen RB, Hasvold P, Aarskog P, Thomsen RW. Statin prescription patterns,  
29 adherence, and attainment of cholesterol treatment goals in routine clinical care: a Danish  
30 population-based study. *Clinical epidemiology*. 2015;7:213.
- 31  
32 45. O'Keeffe AG, Nazareth I, Petersen I. Time trends in the prescription of statins for the primary  
33 prevention of cardiovascular disease in the United Kingdom: a cohort study using The Health  
34 Improvement Network primary care data. *Clinical epidemiology*. 2016;8:123.
- 35  
36 46. García-Gil M, Blanch J, Comas-Cufí M, et al. Patterns of statin use and cholesterol goal  
37 attainment in a high-risk cardiovascular population: A retrospective study of primary care  
38 electronic medical records. *Journal of Clinical Lipidology*. 2016;10(1):134-142.
- 39  
40 47. Svensson E, Nielsen RB, Hasvold P, Aarskog P, Thomsen RW. Statin prescription patterns,  
41 adherence, and attainment of cholesterol treatment goals in routine clinical care: a Danish  
42 population-based study. *Clin Epidemiol*. 2015;7:213-223.
- 43  
44 48. Ferrajolo C, Arcoraci V, Sullo MG, et al. Pattern of Statin Use in Southern Italian Primary  
45 Care: Can Prescription Databases Be Used for Monitoring Long-Term Adherence to the  
46 Treatment? *PLOS ONE*. 2014;9(7):e102146.
- 47  
48 49. Kim CJ, Kim J, Kim KI, et al. 2015 Korean guidelines for the management of dyslipidemia:  
49 executive summary (English translation). *Korean circulation journal*. 2016;46(3):275-306.
- 50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60







## Appendix 1. Drug code of statins in Korea

Drug Names	ATC code	National Code System (Strength and code)		The date of drug entry	
				New drug	First follow on drug
Atorvastatin	C10AA05	10	111501ATB	1999.08.01	2007.01.17
		20	111502ATB		
		40	111503ATB		
		80	111504ATB		
Fluvastatin	C10AA04	20	162401ACH	1994.10.10	N/A
		40	162402ACH		
		80	162403ATR		
Lovastatin	C10AA02	20	185801ATB	1997.08.06	1997.12.11
Pitavastatin	C10AA08	1	470902ATB	2005.01.06	2011.05.24
		2	470901ATB		
		4	470903ATB		
Pravastatin	C10AA03	5	216602ATB	1990.04.10	1994.05.17
		10	216601ATB		
		20	216603ATB		
		40	216604ATB		
Rosuvastatin	C10AA07	5	454003ATB	2002.01.15	2008.11.07
		10	454001ATB		
		20	454002ATB		
Simvastatin	C10AA01	5	227805ATB	1996.08.01	2002.07.09
		10	227803ATB		
		20	227801ATB, 227801ATR		
		40	227802ATB		
		80	227806ATB		
Ezetimibe and atorvastatin	C10BA05	10 + 10	633800ATB		
		10 + 20	633900ATB		
		10 + 40	634800ATB		
Ezetimibe and rosuvastatin	C10BA06	10 + 5	640700ATB		
		10 + 10	640800ATB		
		10 + 20	640900ATB		
Ezetimibe and simvastatin	C10BA02	10 + 10	471000ATB		
		10 + 20	471100ATB		
Fenofibrate and simvastatin	C10BA04	145 + 20	631400ATB		
		145 + 40	631500ATB		

ATC: anatomical therapeutic chemical

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Page #	Recommendation
<b>Title and abstract</b>	1	2	(a) Indicate the study's design with a commonly used term in the title or the abstract
		2	(b) Provide in the abstract an informative and balanced summary of what was done and what was found
<b>Introduction</b>			
Background/rationale	2	7	Explain the scientific background and rationale for the investigation being reported
Objectives	3	7	State specific objectives, including any prespecified hypotheses
<b>Methods</b>			
Study design	4	9-11	Present key elements of study design early in the paper
Setting	5	8-9	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	9-11	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up
		N/A	(b) For matched studies, give matching criteria and number of exposed and unexposed
Variables	7	9-13	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*	9-11	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	N/A	Describe any efforts to address potential sources of bias
Study size	10	N/A	Explain how the study size was arrived at
Quantitative variables	11	9-13	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	9-13	(a) Describe all statistical methods, including those used to control for confounding
		N/A	(b) Describe any methods used to examine subgroups and interactions
		N/A	(c) Explain how missing data were addressed
		N/A	(d) If applicable, explain how loss to follow-up was addressed
		N/A	(e) Describe any sensitivity analyses
<b>Results</b>			
Participants	13*	13-14	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed
		13-14	(b) Give reasons for non-participation at each stage

		N/A	(c) Consider use of a flow diagram
Descriptive data	14*	14-17	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders
		N/A	(b) Indicate number of participants with missing data for each variable of interest
		N/A	(c) Summarise follow-up time (eg, average and total amount)
Outcome data	15*	13-14	Report numbers of outcome events or summary measures over time
Main results	16	13-17	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included
		N/A	(b) Report category boundaries when continuous variables were categorized
		N/A	(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	N/A	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
<b>Discussion</b>			
Key results	18	18	Summarise key results with reference to study objectives
Limitations	19	22-23	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	18-23	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	22-23	Discuss the generalisability (external validity) of the study results
<b>Other information</b>			
Funding	22	24	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.